{"transactions":[{"id":1844870,"issuer":{"id":7461,"kind":"organization","name":"NextCure, Inc."},"owners":[{"id":111954,"kind":"person","name":"Khuong Chau Quang","position":1,"cik":"0001609405","reported_name":"Khuong Chau Quang","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2023-06-23T16:31:02.000Z","date":"2023-06-22","kind":"grant","planned":false,"acquired":true,"shares":14250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests in full on the earlier of June 22, 2024 and the date of the 2024 Annual Meeting of Stockholders."}],"balance_after":14250,"derivative":{"exercise_price":1.62,"expiration_date":"2033-06-21","underlying":"Common Stock","underlying_shares":14250},"source":{"system":"sec-edgar","filing":"0001140361-23-031192","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1609405/000114036123031192/form4.xml","form_type":"4"}},{"id":1853836,"issuer":{"id":4602,"kind":"organization","name":"Damora Therapeutics, Inc.","symbol":"DMRA"},"owners":[{"id":111954,"kind":"person","name":"Khuong Chau Quang","position":1,"cik":"0001609405","reported_name":"Khuong Chau Quang","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-06-15T16:00:06.000Z","date":"2023-06-14","kind":"grant","planned":false,"acquired":true,"shares":18000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Pursuant to the Issuer's Non-Employee Director Compensation Policy, this option was automatically granted on June 14, 2023, the date of the Issuer's 2023 Annual Meeting of Stockholders, with shares subject to the option vesting in equal monthly installments until the first anniversary of the grant date."}],"balance_after":18000,"derivative":{"exercise_price":2.12,"expiration_date":"2033-06-13","underlying":"Common Stock","underlying_shares":18000},"source":{"system":"sec-edgar","filing":"0001209191-23-037283","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1609405/000120919123037283/doc4.xml","form_type":"4"}},{"id":1856004,"issuer":{"id":11851,"kind":"organization","name":"Fusion Pharmaceuticals Inc.","symbol":"FUSN"},"owners":[{"id":111954,"kind":"person","name":"Khuong Chau Quang","position":1,"cik":"0001609405","reported_name":"Khuong Chau Quang","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-06-14T17:08:57.000Z","date":"2023-06-14","kind":"grant","planned":false,"acquired":true,"shares":17000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option fully vests on the earlier of (i) June 14, 2024 or (ii) the 2024 Annual Meeting of Shareholders of Fusion Pharmaceuticals Inc."}],"balance_after":17000,"derivative":{"exercise_price":4.64,"expiration_date":"2033-06-13","underlying":"Common Stock","underlying_shares":17000},"source":{"system":"sec-edgar","filing":"0001209191-23-037093","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1805890/000120919123037093/doc4.xml","form_type":"4"}},{"id":2118130,"issuer":{"id":11851,"kind":"organization","name":"Fusion Pharmaceuticals Inc.","symbol":"FUSN"},"owners":[{"id":111954,"kind":"person","name":"Khuong Chau Quang","position":1,"cik":"0001609405","reported_name":"Khuong Chau Quang","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-11-14T08:31:29.000Z","date":"2022-11-11","kind":"grant","acquired":true,"shares":42093,"price":2.38,"value":100181.34,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported represents the weighted average sales price of shares purchased in multiple transactions at prices ranging from $2.24 to $2.47 per share. The reporting person hereby undertakes, upon request of the staff of the U.S. Securities and Exchange Commission, the Issuer or a security holder of the Issuer, to provide full information regarding the number of shares sold at each separate price."}],"balance_after":42093,"source":{"system":"sec-edgar","filing":"0001209191-22-056481","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1805890/000120919122056481/doc4.xml","form_type":"4"}},{"id":2221785,"issuer":{"id":7461,"kind":"organization","name":"NextCure, Inc."},"owners":[{"id":111954,"kind":"person","name":"Khuong Chau Quang","position":1,"cik":"0001609405","reported_name":"Khuong Chau Quang","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-06-24T17:25:40.000Z","date":"2022-06-23","kind":"grant","acquired":true,"shares":14250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests in full on the earlier of June 23, 2023 and the date of the 2023 Annual Meeting of Stockholders."}],"balance_after":14250,"derivative":{"exercise_price":4.77,"expiration_date":"2032-06-22","underlying":"Common Stock","underlying_shares":14250},"source":{"system":"sec-edgar","filing":"0001567619-22-013368","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1609405/000156761922013368/doc1.xml","form_type":"4"}},{"id":2224240,"issuer":{"id":11851,"kind":"organization","name":"Fusion Pharmaceuticals Inc.","symbol":"FUSN"},"owners":[{"id":111954,"kind":"person","name":"Khuong Chau Quang","position":1,"cik":"0001609405","reported_name":"Khuong Chau Quang","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-06-22T19:12:26.000Z","date":"2022-06-14","kind":"grant","acquired":true,"shares":17000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option fully vests on the earlier of (i) June 14, 2023 or (ii) the 2023 Annual Meeting of Shareholders of Fusion Pharmaceuticals Inc."}],"balance_after":17000,"derivative":{"exercise_price":3.6,"expiration_date":"2032-06-13","underlying":"Common Stock","underlying_shares":17000},"source":{"system":"sec-edgar","filing":"0001209191-22-038771","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1805890/000120919122038771/doc4.xml","form_type":"4"}},{"id":2231086,"issuer":{"id":4602,"kind":"organization","name":"Damora Therapeutics, Inc.","symbol":"DMRA"},"owners":[{"id":111954,"kind":"person","name":"Khuong Chau Quang","position":1,"cik":"0001609405","reported_name":"Khuong Chau Quang","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"/s/ Jonathan Freve, attorney-in-fact","published_at":"2022-06-15T16:00:17.000Z","date":"2022-06-14","kind":"grant","acquired":true,"shares":18000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Pursuant to the Issuer's Non-Employee Director Compensation Policy, this option was automatically granted on June 14, 2022, the date of the Issuer's 2022 Annual Meeting of Stockholder, with shares subject to the option vesting in equal monthly installments until the first anniversary of the grant date."}],"balance_after":18000,"derivative":{"exercise_price":1.98,"expiration_date":"2032-06-13","underlying":"Common Stock","underlying_shares":18000},"source":{"system":"sec-edgar","filing":"0001209191-22-036933","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1609405/000120919122036933/doc4.xml","form_type":"4"}},{"id":2502241,"issuer":{"id":4602,"kind":"organization","name":"Damora Therapeutics, Inc.","symbol":"DMRA"},"owners":[{"id":111954,"kind":"person","name":"Khuong Chau Quang","position":1,"cik":"0001609405","reported_name":"Khuong Chau Quang","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2021-11-19T17:00:34.000Z","date":"2021-11-17","kind":"grant","acquired":true,"shares":9000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"This stock option was awarded to the Reporting Person in recognition for his work as a board member with respect to the strategic efforts of the Company."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Shares subject to the option vest in equal monthly installments until the first anniversary of the grant date."}],"balance_after":9000,"derivative":{"exercise_price":3.23,"expiration_date":"2031-11-16","underlying":"Common Stock","underlying_shares":9000},"source":{"system":"sec-edgar","filing":"0001209191-21-065847","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1609405/000120919121065847/doc4.xml","form_type":"4"}},{"id":2653075,"issuer":{"id":7461,"kind":"organization","name":"NextCure, Inc."},"owners":[{"id":111954,"kind":"person","name":"Khuong Chau Quang","position":1,"cik":"0001609405","reported_name":"Khuong Chau Quang","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-06-28T18:09:31.000Z","date":"2021-06-24","kind":"grant","acquired":true,"shares":14250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests in full on the earlier of June 24, 2022 and the date of the 2022 Annual Meeting of Stockholders."}],"balance_after":14250,"derivative":{"exercise_price":8.21,"expiration_date":"2031-06-23","underlying":"Common Stock","underlying_shares":14250},"source":{"system":"sec-edgar","filing":"0001567619-21-012666","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1609405/000156761921012666/doc1.xml","form_type":"4"}},{"id":2679492,"issuer":{"id":11851,"kind":"organization","name":"Fusion Pharmaceuticals Inc.","symbol":"FUSN"},"owners":[{"id":111954,"kind":"person","name":"Khuong Chau Quang","position":1,"cik":"0001609405","reported_name":"Khuong Chau Quang","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-06-07T16:16:38.000Z","date":"2021-06-04","kind":"grant","acquired":true,"shares":17000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option fully vests on the earlier of (i) June 4, 2022 or (ii) the 2022 Annual Meeting of Shareholders of Fusion Pharmaceuticals Inc."}],"balance_after":17000,"derivative":{"exercise_price":8.15,"expiration_date":"2031-06-03","underlying":"Common Stock","underlying_shares":17000},"source":{"system":"sec-edgar","filing":"0001209191-21-038578","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1805890/000120919121038578/doc4.xml","form_type":"4"}},{"id":2690704,"issuer":{"id":4602,"kind":"organization","name":"Damora Therapeutics, Inc.","symbol":"DMRA"},"owners":[{"id":111954,"kind":"person","name":"Khuong Chau Quang","position":1,"cik":"0001609405","reported_name":"Khuong Chau Quang","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2021-05-28T16:00:20.000Z","date":"2021-05-26","kind":"grant","acquired":true,"shares":18000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Pursuant to the Issuer's Non-Employee Director Compensation Policy, this option was automatically granted on May 26, 2021, the date of the Issuer's 2021 Annual Meeting of Stockholder, with shares subject to the option vesting in equal monthly installments until the first anniversary of the grant date. Pursuant to an agreement with OrbiMed Advisors LLC, OrbiMed Capital GP VII LLC, OrbiMed Advisors Israel II Limited, and OrbiMed Israel GP II, L.P., the Reporting Person is obligated to transfer any securities issued under any such stock options or other awards, or the economic benefit thereof, to OrbiMed Advisors LLC, OrbiMed Capital GP VII LLC, OrbiMed Advisors Israel II Limited, and OrbiMed Israel GP II, L.P., which will in turn ensure that such securities or economic benefits are provided to OrbiMed Private Investments VII, L.P. and OrbiMed Israel Partners II, L.P."}],"balance_after":18000,"derivative":{"exercise_price":4.93,"expiration_date":"2031-05-25","underlying":"Common Stock","underlying_shares":18000},"source":{"system":"sec-edgar","filing":"0001209191-21-036509","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1609405/000120919121036509/doc4.xml","form_type":"4"}},{"id":2741757,"issuer":{"id":7801,"kind":"organization","name":"SYNLOGIC, INC."},"owners":[{"id":111954,"kind":"person","name":"Khuong Chau Quang","position":1,"cik":"0001609405","reported_name":"Khuong Chau Quang","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock, $0.001 par value","published_at":"2021-04-22T21:11:02.000Z","date":"2021-04-20","kind":"grant","acquired":true,"shares":1666666,"price":3,"value":4999998.0,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"These shares of the Issuer's common stock were sold in an underwritten public offering at a price of $3.00 per share."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares of the Issuer's common stock are held of record by OrbiMed Private Investments VI, LP (\"OPI VI\"). OrbiMed Capital GP VI LLC (\"GP V\") is the general partner of OPI VI, and OrbiMed Advisors LLC (\"OrbiMed Advisors\"), a registered investment adviser under the Investment Advisors Act of 1940, as amended, is the managing member of GP VI. The Reporting Person is an employee of OrbiMed Advisors. By virtue of such relationships, GP VI and OrbiMed Advisors may be deemed to have voting and investment power with respect to the securities held by OPI VI noted above and as a result may be deemed to beneficially own such securities for purposes of Rule 13d-3 under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"). OrbiMed Advisors exercises this investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and Jonathan T. Silverstein, each of whom disclaims beneficial ownership of the Shares held by OPI VI."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Each of the Reporting Person, GP VI, and OrbiMed Advisors disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Exchange Act, except to the extent of his or its pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Person, GP VI or OrbiMed Advisors is a beneficial owner of such securities for the purposes of Section 16 of the Exchange Act, or for any other purposes."}],"balance_after":3696662,"source":{"system":"sec-edgar","filing":"0000947871-21-000454","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1527599/000094787121000454/ownership.xml","form_type":"4"}},{"id":2992217,"issuer":{"id":4602,"kind":"organization","name":"Damora Therapeutics, Inc.","symbol":"DMRA"},"owners":[{"id":111954,"kind":"person","name":"Khuong Chau Quang","position":1,"cik":"0001609405","reported_name":"Khuong Chau Quang","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series D Preferred Stock","published_at":"2020-11-04T20:00:11.000Z","date":"2020-11-02","kind":"exercise","acquired":false,"shares":73773,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The Series C-2 Preferred Stock, Series C-4 Preferred Stock, Series C-5 Preferred Stock, and Series D Preferred Stock (collectively, the \"Preferred Stock\") was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock converted into Common Stock at a ratio of 2.59970:1 upon the closing of the Issuer's initial public offering without payment of additional consideration. The Preferred Stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The Series C-2 Preferred Stock, Series C-4 Preferred Stock, Series C-5 Preferred Stock, and Series D Preferred Stock (collectively, the \"Preferred Stock\") was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock converted into Common Stock at a ratio of 2.59970:1 upon the closing of the Issuer's initial public offering without payment of additional consideration. The Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Series C-2 Preferred Stock, Series C-4 Preferred Stock, Series C-5 Preferred Stock, and Series D Preferred Stock (collectively, the \"Preferred Stock\") was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock converted into Common Stock at a ratio of 2.59970:1 upon the closing of the Issuer's initial public offering without payment of additional consideration. The Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The Series C-2 Preferred Stock, Series C-4 Preferred Stock, Series C-5 Preferred Stock, and Series D Preferred Stock (collectively, the \"Preferred Stock\") was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock converted into Common Stock at a ratio of 2.59970:1 upon the closing of the Issuer's initial public offering without payment of additional consideration. The Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"These securities are held of record by OrbiMed Genesis Master Fund, L.P. (\"Genesis Master Fund\"). OrbiMed Genesis GP LLC (\"Genesis GP\") is the general partner of Genesis Master Fund and OrbiMed Advisors is the managing member of Genesis GP. By virtue of such relationships, Genesis GP and OrbiMed Advisors may be deemed to have voting and investment power over the securities held by Genesis Master Fund and as a result may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises its investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and Jonathan T. Silverstein, each of whom disclaims beneficial ownership of the securities held by Genesis Master Fund."}],"balance_after":0,"derivative":{"underlying":"Common Shares","underlying_shares":191787},"source":{"system":"sec-edgar","filing":"0000899243-20-030411","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":17,"url":"https://www.sec.gov/Archives/edgar/data/1609405/000089924320030411/doc4.xml","form_type":"4"}},{"id":2992216,"issuer":{"id":4602,"kind":"organization","name":"Damora Therapeutics, Inc.","symbol":"DMRA"},"owners":[{"id":111954,"kind":"person","name":"Khuong Chau Quang","position":1,"cik":"0001609405","reported_name":"Khuong Chau Quang","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series D Preferred Stock","published_at":"2020-11-04T20:00:11.000Z","date":"2020-11-02","kind":"exercise","acquired":false,"shares":59350,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The Series C-2 Preferred Stock, Series C-4 Preferred Stock, Series C-5 Preferred Stock, and Series D Preferred Stock (collectively, the \"Preferred Stock\") was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock converted into Common Stock at a ratio of 2.59970:1 upon the closing of the Issuer's initial public offering without payment of additional consideration. The Preferred Stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The Series C-2 Preferred Stock, Series C-4 Preferred Stock, Series C-5 Preferred Stock, and Series D Preferred Stock (collectively, the \"Preferred Stock\") was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock converted into Common Stock at a ratio of 2.59970:1 upon the closing of the Issuer's initial public offering without payment of additional consideration. The Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Series C-2 Preferred Stock, Series C-4 Preferred Stock, Series C-5 Preferred Stock, and Series D Preferred Stock (collectively, the \"Preferred Stock\") was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock converted into Common Stock at a ratio of 2.59970:1 upon the closing of the Issuer's initial public offering without payment of additional consideration. The Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The Series C-2 Preferred Stock, Series C-4 Preferred Stock, Series C-5 Preferred Stock, and Series D Preferred Stock (collectively, the \"Preferred Stock\") was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock converted into Common Stock at a ratio of 2.59970:1 upon the closing of the Issuer's initial public offering without payment of additional consideration. The Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These securities are held of record by OrbiMed Israel Partners II, L.P. (\"OIP II\"). OrbiMed Israel is the general partner of OIP II, and OrbiMed Limited is the managing member of OrbiMed Israel. By virtue of such relationships, OrbiMed Israel and OrbiMed Limited may be deemed to have voting and investment power over the securities held by OIP II and as a result may be deemed to have beneficial ownership over such securities. OrbiMed Limited exercises its investment and voting power through a management committee comprised of Carl L. Gordon, Jonathan Silverstein, Nissim Darvish, Anat Naschitz, and Erez Chimovits, each of whom disclaims beneficial ownership of the securities held by OIP II."}],"balance_after":0,"derivative":{"underlying":"Common Shares","underlying_shares":154292},"source":{"system":"sec-edgar","filing":"0000899243-20-030411","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":16,"url":"https://www.sec.gov/Archives/edgar/data/1609405/000089924320030411/doc4.xml","form_type":"4"}},{"id":2992215,"issuer":{"id":4602,"kind":"organization","name":"Damora Therapeutics, Inc.","symbol":"DMRA"},"owners":[{"id":111954,"kind":"person","name":"Khuong Chau Quang","position":1,"cik":"0001609405","reported_name":"Khuong Chau Quang","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series D Preferred Stock","published_at":"2020-11-04T20:00:11.000Z","date":"2020-11-02","kind":"exercise","acquired":false,"shares":148395,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The Series C-2 Preferred Stock, Series C-4 Preferred Stock, Series C-5 Preferred Stock, and Series D Preferred Stock (collectively, the \"Preferred Stock\") was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock converted into Common Stock at a ratio of 2.59970:1 upon the closing of the Issuer's initial public offering without payment of additional consideration. The Preferred Stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The Series C-2 Preferred Stock, Series C-4 Preferred Stock, Series C-5 Preferred Stock, and Series D Preferred Stock (collectively, the \"Preferred Stock\") was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock converted into Common Stock at a ratio of 2.59970:1 upon the closing of the Issuer's initial public offering without payment of additional consideration. The Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Series C-2 Preferred Stock, Series C-4 Preferred Stock, Series C-5 Preferred Stock, and Series D Preferred Stock (collectively, the \"Preferred Stock\") was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock converted into Common Stock at a ratio of 2.59970:1 upon the closing of the Issuer's initial public offering without payment of additional consideration. The Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The Series C-2 Preferred Stock, Series C-4 Preferred Stock, Series C-5 Preferred Stock, and Series D Preferred Stock (collectively, the \"Preferred Stock\") was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock converted into Common Stock at a ratio of 2.59970:1 upon the closing of the Issuer's initial public offering without payment of additional consideration. The Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held of record by OrbiMed Private Investments VII, LP (\"OPI VII\"). OrbiMed Capital GP VII LLC (\"GP VII\") is the general partner of OPI VII and OrbiMed Advisors LLC (\"OrbiMed Advisors\") is the managing member of GP VII. By virtue of such relationships, GP VII and OrbiMed Advisors may be deemed to have voting and investment power over the securities held by OPI VII and as a result may be deemed to have beneficial ownership over such securities. The Reporting Person is an employee of OrbiMed Advisors. OrbiMed Advisors exercises its investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and Jonathan T. Silverstein, each of whom disclaims beneficial ownership of the securities held by OPI VII."}],"balance_after":0,"derivative":{"underlying":"Common Shares","underlying_shares":385782},"source":{"system":"sec-edgar","filing":"0000899243-20-030411","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":15,"url":"https://www.sec.gov/Archives/edgar/data/1609405/000089924320030411/doc4.xml","form_type":"4"}},{"id":2992214,"issuer":{"id":4602,"kind":"organization","name":"Damora Therapeutics, Inc.","symbol":"DMRA"},"owners":[{"id":111954,"kind":"person","name":"Khuong Chau Quang","position":1,"cik":"0001609405","reported_name":"Khuong Chau Quang","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series C-5 Preferred Stock","published_at":"2020-11-04T20:00:11.000Z","date":"2020-11-02","kind":"exercise","acquired":false,"shares":31147,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The Series C-2 Preferred Stock, Series C-4 Preferred Stock, Series C-5 Preferred Stock, and Series D Preferred Stock (collectively, the \"Preferred Stock\") was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock converted into Common Stock at a ratio of 2.59970:1 upon the closing of the Issuer's initial public offering without payment of additional consideration. The Preferred Stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The Series C-2 Preferred Stock, Series C-4 Preferred Stock, Series C-5 Preferred Stock, and Series D Preferred Stock (collectively, the \"Preferred Stock\") was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock converted into Common Stock at a ratio of 2.59970:1 upon the closing of the Issuer's initial public offering without payment of additional consideration. The Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Series C-2 Preferred Stock, Series C-4 Preferred Stock, Series C-5 Preferred Stock, and Series D Preferred Stock (collectively, the \"Preferred Stock\") was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock converted into Common Stock at a ratio of 2.59970:1 upon the closing of the Issuer's initial public offering without payment of additional consideration. The Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The Series C-2 Preferred Stock, Series C-4 Preferred Stock, Series C-5 Preferred Stock, and Series D Preferred Stock (collectively, the \"Preferred Stock\") was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock converted into Common Stock at a ratio of 2.59970:1 upon the closing of the Issuer's initial public offering without payment of additional consideration. The Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These securities are held of record by OrbiMed Israel Partners II, L.P. (\"OIP II\"). OrbiMed Israel is the general partner of OIP II, and OrbiMed Limited is the managing member of OrbiMed Israel. By virtue of such relationships, OrbiMed Israel and OrbiMed Limited may be deemed to have voting and investment power over the securities held by OIP II and as a result may be deemed to have beneficial ownership over such securities. OrbiMed Limited exercises its investment and voting power through a management committee comprised of Carl L. Gordon, Jonathan Silverstein, Nissim Darvish, Anat Naschitz, and Erez Chimovits, each of whom disclaims beneficial ownership of the securities held by OIP II."}],"balance_after":0,"derivative":{"underlying":"Common Shares","underlying_shares":80972},"source":{"system":"sec-edgar","filing":"0000899243-20-030411","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/1609405/000089924320030411/doc4.xml","form_type":"4"}},{"id":2992213,"issuer":{"id":4602,"kind":"organization","name":"Damora Therapeutics, Inc.","symbol":"DMRA"},"owners":[{"id":111954,"kind":"person","name":"Khuong Chau Quang","position":1,"cik":"0001609405","reported_name":"Khuong Chau Quang","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series C-5 Preferred Stock","published_at":"2020-11-04T20:00:11.000Z","date":"2020-11-02","kind":"exercise","acquired":false,"shares":77866,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The Series C-2 Preferred Stock, Series C-4 Preferred Stock, Series C-5 Preferred Stock, and Series D Preferred Stock (collectively, the \"Preferred Stock\") was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock converted into Common Stock at a ratio of 2.59970:1 upon the closing of the Issuer's initial public offering without payment of additional consideration. The Preferred Stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The Series C-2 Preferred Stock, Series C-4 Preferred Stock, Series C-5 Preferred Stock, and Series D Preferred Stock (collectively, the \"Preferred Stock\") was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock converted into Common Stock at a ratio of 2.59970:1 upon the closing of the Issuer's initial public offering without payment of additional consideration. The Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Series C-2 Preferred Stock, Series C-4 Preferred Stock, Series C-5 Preferred Stock, and Series D Preferred Stock (collectively, the \"Preferred Stock\") was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock converted into Common Stock at a ratio of 2.59970:1 upon the closing of the Issuer's initial public offering without payment of additional consideration. The Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The Series C-2 Preferred Stock, Series C-4 Preferred Stock, Series C-5 Preferred Stock, and Series D Preferred Stock (collectively, the \"Preferred Stock\") was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock converted into Common Stock at a ratio of 2.59970:1 upon the closing of the Issuer's initial public offering without payment of additional consideration. The Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held of record by OrbiMed Private Investments VII, LP (\"OPI VII\"). OrbiMed Capital GP VII LLC (\"GP VII\") is the general partner of OPI VII and OrbiMed Advisors LLC (\"OrbiMed Advisors\") is the managing member of GP VII. By virtue of such relationships, GP VII and OrbiMed Advisors may be deemed to have voting and investment power over the securities held by OPI VII and as a result may be deemed to have beneficial ownership over such securities. The Reporting Person is an employee of OrbiMed Advisors. OrbiMed Advisors exercises its investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and Jonathan T. Silverstein, each of whom disclaims beneficial ownership of the securities held by OPI VII."}],"balance_after":0,"derivative":{"underlying":"Common Shares","underlying_shares":202428},"source":{"system":"sec-edgar","filing":"0000899243-20-030411","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1609405/000089924320030411/doc4.xml","form_type":"4"}},{"id":2992212,"issuer":{"id":4602,"kind":"organization","name":"Damora Therapeutics, Inc.","symbol":"DMRA"},"owners":[{"id":111954,"kind":"person","name":"Khuong Chau Quang","position":1,"cik":"0001609405","reported_name":"Khuong Chau Quang","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series C-4 Preferred Stock","published_at":"2020-11-04T20:00:11.000Z","date":"2020-11-02","kind":"exercise","acquired":false,"shares":109013,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The Series C-2 Preferred Stock, Series C-4 Preferred Stock, Series C-5 Preferred Stock, and Series D Preferred Stock (collectively, the \"Preferred Stock\") was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock converted into Common Stock at a ratio of 2.59970:1 upon the closing of the Issuer's initial public offering without payment of additional consideration. The Preferred Stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The Series C-2 Preferred Stock, Series C-4 Preferred Stock, Series C-5 Preferred Stock, and Series D Preferred Stock (collectively, the \"Preferred Stock\") was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock converted into Common Stock at a ratio of 2.59970:1 upon the closing of the Issuer's initial public offering without payment of additional consideration. The Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Series C-2 Preferred Stock, Series C-4 Preferred Stock, Series C-5 Preferred Stock, and Series D Preferred Stock (collectively, the \"Preferred Stock\") was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock converted into Common Stock at a ratio of 2.59970:1 upon the closing of the Issuer's initial public offering without payment of additional consideration. The Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The Series C-2 Preferred Stock, Series C-4 Preferred Stock, Series C-5 Preferred Stock, and Series D Preferred Stock (collectively, the \"Preferred Stock\") was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock converted into Common Stock at a ratio of 2.59970:1 upon the closing of the Issuer's initial public offering without payment of additional consideration. The Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These securities are held of record by OrbiMed Israel Partners II, L.P. (\"OIP II\"). OrbiMed Israel is the general partner of OIP II, and OrbiMed Limited is the managing member of OrbiMed Israel. By virtue of such relationships, OrbiMed Israel and OrbiMed Limited may be deemed to have voting and investment power over the securities held by OIP II and as a result may be deemed to have beneficial ownership over such securities. OrbiMed Limited exercises its investment and voting power through a management committee comprised of Carl L. Gordon, Jonathan Silverstein, Nissim Darvish, Anat Naschitz, and Erez Chimovits, each of whom disclaims beneficial ownership of the securities held by OIP II."}],"balance_after":0,"derivative":{"underlying":"Common Shares","underlying_shares":283402},"source":{"system":"sec-edgar","filing":"0000899243-20-030411","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1609405/000089924320030411/doc4.xml","form_type":"4"}},{"id":2992211,"issuer":{"id":4602,"kind":"organization","name":"Damora Therapeutics, Inc.","symbol":"DMRA"},"owners":[{"id":111954,"kind":"person","name":"Khuong Chau Quang","position":1,"cik":"0001609405","reported_name":"Khuong Chau Quang","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series C-4 Preferred Stock","published_at":"2020-11-04T20:00:11.000Z","date":"2020-11-02","kind":"exercise","acquired":false,"shares":272533,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The Series C-2 Preferred Stock, Series C-4 Preferred Stock, Series C-5 Preferred Stock, and Series D Preferred Stock (collectively, the \"Preferred Stock\") was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock converted into Common Stock at a ratio of 2.59970:1 upon the closing of the Issuer's initial public offering without payment of additional consideration. The Preferred Stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The Series C-2 Preferred Stock, Series C-4 Preferred Stock, Series C-5 Preferred Stock, and Series D Preferred Stock (collectively, the \"Preferred Stock\") was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock converted into Common Stock at a ratio of 2.59970:1 upon the closing of the Issuer's initial public offering without payment of additional consideration. The Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Series C-2 Preferred Stock, Series C-4 Preferred Stock, Series C-5 Preferred Stock, and Series D Preferred Stock (collectively, the \"Preferred Stock\") was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock converted into Common Stock at a ratio of 2.59970:1 upon the closing of the Issuer's initial public offering without payment of additional consideration. The Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The Series C-2 Preferred Stock, Series C-4 Preferred Stock, Series C-5 Preferred Stock, and Series D Preferred Stock (collectively, the \"Preferred Stock\") was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock converted into Common Stock at a ratio of 2.59970:1 upon the closing of the Issuer's initial public offering without payment of additional consideration. The Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held of record by OrbiMed Private Investments VII, LP (\"OPI VII\"). OrbiMed Capital GP VII LLC (\"GP VII\") is the general partner of OPI VII and OrbiMed Advisors LLC (\"OrbiMed Advisors\") is the managing member of GP VII. By virtue of such relationships, GP VII and OrbiMed Advisors may be deemed to have voting and investment power over the securities held by OPI VII and as a result may be deemed to have beneficial ownership over such securities. The Reporting Person is an employee of OrbiMed Advisors. OrbiMed Advisors exercises its investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and Jonathan T. Silverstein, each of whom disclaims beneficial ownership of the securities held by OPI VII."}],"balance_after":0,"derivative":{"underlying":"Common Shares","underlying_shares":708504},"source":{"system":"sec-edgar","filing":"0000899243-20-030411","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1609405/000089924320030411/doc4.xml","form_type":"4"}},{"id":2992210,"issuer":{"id":4602,"kind":"organization","name":"Damora Therapeutics, Inc.","symbol":"DMRA"},"owners":[{"id":111954,"kind":"person","name":"Khuong Chau Quang","position":1,"cik":"0001609405","reported_name":"Khuong Chau Quang","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series C-2 Preferred Stock","published_at":"2020-11-04T20:00:11.000Z","date":"2020-11-02","kind":"exercise","acquired":false,"shares":116800,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The Series C-2 Preferred Stock, Series C-4 Preferred Stock, Series C-5 Preferred Stock, and Series D Preferred Stock (collectively, the \"Preferred Stock\") was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock converted into Common Stock at a ratio of 2.59970:1 upon the closing of the Issuer's initial public offering without payment of additional consideration. The Preferred Stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The Series C-2 Preferred Stock, Series C-4 Preferred Stock, Series C-5 Preferred Stock, and Series D Preferred Stock (collectively, the \"Preferred Stock\") was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock converted into Common Stock at a ratio of 2.59970:1 upon the closing of the Issuer's initial public offering without payment of additional consideration. The Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Series C-2 Preferred Stock, Series C-4 Preferred Stock, Series C-5 Preferred Stock, and Series D Preferred Stock (collectively, the \"Preferred Stock\") was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock converted into Common Stock at a ratio of 2.59970:1 upon the closing of the Issuer's initial public offering without payment of additional consideration. The Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The Series C-2 Preferred Stock, Series C-4 Preferred Stock, Series C-5 Preferred Stock, and Series D Preferred Stock (collectively, the \"Preferred Stock\") was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock converted into Common Stock at a ratio of 2.59970:1 upon the closing of the Issuer's initial public offering without payment of additional consideration. The Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These securities are held of record by OrbiMed Israel Partners II, L.P. (\"OIP II\"). OrbiMed Israel is the general partner of OIP II, and OrbiMed Limited is the managing member of OrbiMed Israel. By virtue of such relationships, OrbiMed Israel and OrbiMed Limited may be deemed to have voting and investment power over the securities held by OIP II and as a result may be deemed to have beneficial ownership over such securities. OrbiMed Limited exercises its investment and voting power through a management committee comprised of Carl L. Gordon, Jonathan Silverstein, Nissim Darvish, Anat Naschitz, and Erez Chimovits, each of whom disclaims beneficial ownership of the securities held by OIP II."}],"balance_after":0,"derivative":{"underlying":"Common Shares","underlying_shares":303645},"source":{"system":"sec-edgar","filing":"0000899243-20-030411","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1609405/000089924320030411/doc4.xml","form_type":"4"}},{"id":2992209,"issuer":{"id":4602,"kind":"organization","name":"Damora Therapeutics, Inc.","symbol":"DMRA"},"owners":[{"id":111954,"kind":"person","name":"Khuong Chau Quang","position":1,"cik":"0001609405","reported_name":"Khuong Chau Quang","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series C-2 Preferred Stock","published_at":"2020-11-04T20:00:11.000Z","date":"2020-11-02","kind":"exercise","acquired":false,"shares":291999,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The Series C-2 Preferred Stock, Series C-4 Preferred Stock, Series C-5 Preferred Stock, and Series D Preferred Stock (collectively, the \"Preferred Stock\") was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock converted into Common Stock at a ratio of 2.59970:1 upon the closing of the Issuer's initial public offering without payment of additional consideration. The Preferred Stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The Series C-2 Preferred Stock, Series C-4 Preferred Stock, Series C-5 Preferred Stock, and Series D Preferred Stock (collectively, the \"Preferred Stock\") was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock converted into Common Stock at a ratio of 2.59970:1 upon the closing of the Issuer's initial public offering without payment of additional consideration. The Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Series C-2 Preferred Stock, Series C-4 Preferred Stock, Series C-5 Preferred Stock, and Series D Preferred Stock (collectively, the \"Preferred Stock\") was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock converted into Common Stock at a ratio of 2.59970:1 upon the closing of the Issuer's initial public offering without payment of additional consideration. The Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The Series C-2 Preferred Stock, Series C-4 Preferred Stock, Series C-5 Preferred Stock, and Series D Preferred Stock (collectively, the \"Preferred Stock\") was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock converted into Common Stock at a ratio of 2.59970:1 upon the closing of the Issuer's initial public offering without payment of additional consideration. The Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held of record by OrbiMed Private Investments VII, LP (\"OPI VII\"). OrbiMed Capital GP VII LLC (\"GP VII\") is the general partner of OPI VII and OrbiMed Advisors LLC (\"OrbiMed Advisors\") is the managing member of GP VII. By virtue of such relationships, GP VII and OrbiMed Advisors may be deemed to have voting and investment power over the securities held by OPI VII and as a result may be deemed to have beneficial ownership over such securities. The Reporting Person is an employee of OrbiMed Advisors. OrbiMed Advisors exercises its investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and Jonathan T. Silverstein, each of whom disclaims beneficial ownership of the securities held by OPI VII."}],"balance_after":0,"derivative":{"underlying":"Common Shares","underlying_shares":759110},"source":{"system":"sec-edgar","filing":"0000899243-20-030411","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1609405/000089924320030411/doc4.xml","form_type":"4"}},{"id":2992208,"issuer":{"id":4602,"kind":"organization","name":"Damora Therapeutics, Inc.","symbol":"DMRA"},"owners":[{"id":111954,"kind":"person","name":"Khuong Chau Quang","position":1,"cik":"0001609405","reported_name":"Khuong Chau Quang","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series D Preferred Stock","published_at":"2020-11-04T20:00:11.000Z","date":"2020-09-25","kind":"grant","acquired":false,"shares":73773,"price":27.11,"value":1999986.03,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The Series C-2 Preferred Stock, Series C-4 Preferred Stock, Series C-5 Preferred Stock, and Series D Preferred Stock (collectively, the \"Preferred Stock\") was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock converted into Common Stock at a ratio of 2.59970:1 upon the closing of the Issuer's initial public offering without payment of additional consideration. The Preferred Stock had no expiration date."},{"field":"kind","element":"transactionCoding","label":"F5","text":"This transaction occurred prior to the Issuer's initial public offering and is being reported on Form 4 solely for purposes of compliance with Rule 16a-2(a) under the Securities Exchange Act of 1934, as amended. The securities covered by such transaction were previously included on the Reporting Person's Form 3."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Series C-2 Preferred Stock, Series C-4 Preferred Stock, Series C-5 Preferred Stock, and Series D Preferred Stock (collectively, the \"Preferred Stock\") was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock converted into Common Stock at a ratio of 2.59970:1 upon the closing of the Issuer's initial public offering without payment of additional consideration. The Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The Series C-2 Preferred Stock, Series C-4 Preferred Stock, Series C-5 Preferred Stock, and Series D Preferred Stock (collectively, the \"Preferred Stock\") was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock converted into Common Stock at a ratio of 2.59970:1 upon the closing of the Issuer's initial public offering without payment of additional consideration. The Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"These securities are held of record by OrbiMed Genesis Master Fund, L.P. (\"Genesis Master Fund\"). OrbiMed Genesis GP LLC (\"Genesis GP\") is the general partner of Genesis Master Fund and OrbiMed Advisors is the managing member of Genesis GP. By virtue of such relationships, Genesis GP and OrbiMed Advisors may be deemed to have voting and investment power over the securities held by Genesis Master Fund and as a result may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises its investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and Jonathan T. Silverstein, each of whom disclaims beneficial ownership of the securities held by Genesis Master Fund."}],"balance_after":73773,"derivative":{"underlying":"Common Shares","underlying_shares":191787},"source":{"system":"sec-edgar","filing":"0000899243-20-030411","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1609405/000089924320030411/doc4.xml","form_type":"4"}},{"id":2992207,"issuer":{"id":4602,"kind":"organization","name":"Damora Therapeutics, Inc.","symbol":"DMRA"},"owners":[{"id":111954,"kind":"person","name":"Khuong Chau Quang","position":1,"cik":"0001609405","reported_name":"Khuong Chau Quang","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series D Preferred Stock","published_at":"2020-11-04T20:00:11.000Z","date":"2020-09-25","kind":"grant","acquired":false,"shares":59350,"price":27.11,"value":1608978.5,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The Series C-2 Preferred Stock, Series C-4 Preferred Stock, Series C-5 Preferred Stock, and Series D Preferred Stock (collectively, the \"Preferred Stock\") was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock converted into Common Stock at a ratio of 2.59970:1 upon the closing of the Issuer's initial public offering without payment of additional consideration. The Preferred Stock had no expiration date."},{"field":"kind","element":"transactionCoding","label":"F5","text":"This transaction occurred prior to the Issuer's initial public offering and is being reported on Form 4 solely for purposes of compliance with Rule 16a-2(a) under the Securities Exchange Act of 1934, as amended. The securities covered by such transaction were previously included on the Reporting Person's Form 3."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Series C-2 Preferred Stock, Series C-4 Preferred Stock, Series C-5 Preferred Stock, and Series D Preferred Stock (collectively, the \"Preferred Stock\") was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock converted into Common Stock at a ratio of 2.59970:1 upon the closing of the Issuer's initial public offering without payment of additional consideration. The Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The Series C-2 Preferred Stock, Series C-4 Preferred Stock, Series C-5 Preferred Stock, and Series D Preferred Stock (collectively, the \"Preferred Stock\") was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock converted into Common Stock at a ratio of 2.59970:1 upon the closing of the Issuer's initial public offering without payment of additional consideration. The Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These securities are held of record by OrbiMed Israel Partners II, L.P. (\"OIP II\"). OrbiMed Israel is the general partner of OIP II, and OrbiMed Limited is the managing member of OrbiMed Israel. By virtue of such relationships, OrbiMed Israel and OrbiMed Limited may be deemed to have voting and investment power over the securities held by OIP II and as a result may be deemed to have beneficial ownership over such securities. OrbiMed Limited exercises its investment and voting power through a management committee comprised of Carl L. Gordon, Jonathan Silverstein, Nissim Darvish, Anat Naschitz, and Erez Chimovits, each of whom disclaims beneficial ownership of the securities held by OIP II."}],"balance_after":59350,"derivative":{"underlying":"Common Shares","underlying_shares":154292},"source":{"system":"sec-edgar","filing":"0000899243-20-030411","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1609405/000089924320030411/doc4.xml","form_type":"4"}},{"id":2992206,"issuer":{"id":4602,"kind":"organization","name":"Damora Therapeutics, Inc.","symbol":"DMRA"},"owners":[{"id":111954,"kind":"person","name":"Khuong Chau Quang","position":1,"cik":"0001609405","reported_name":"Khuong Chau Quang","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series D Preferred Stock","published_at":"2020-11-04T20:00:11.000Z","date":"2020-09-25","kind":"grant","acquired":false,"shares":148395,"price":27.11,"value":4022988.45,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The Series C-2 Preferred Stock, Series C-4 Preferred Stock, Series C-5 Preferred Stock, and Series D Preferred Stock (collectively, the \"Preferred Stock\") was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock converted into Common Stock at a ratio of 2.59970:1 upon the closing of the Issuer's initial public offering without payment of additional consideration. The Preferred Stock had no expiration date."},{"field":"kind","element":"transactionCoding","label":"F5","text":"This transaction occurred prior to the Issuer's initial public offering and is being reported on Form 4 solely for purposes of compliance with Rule 16a-2(a) under the Securities Exchange Act of 1934, as amended. The securities covered by such transaction were previously included on the Reporting Person's Form 3."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Series C-2 Preferred Stock, Series C-4 Preferred Stock, Series C-5 Preferred Stock, and Series D Preferred Stock (collectively, the \"Preferred Stock\") was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock converted into Common Stock at a ratio of 2.59970:1 upon the closing of the Issuer's initial public offering without payment of additional consideration. The Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The Series C-2 Preferred Stock, Series C-4 Preferred Stock, Series C-5 Preferred Stock, and Series D Preferred Stock (collectively, the \"Preferred Stock\") was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock converted into Common Stock at a ratio of 2.59970:1 upon the closing of the Issuer's initial public offering without payment of additional consideration. The Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held of record by OrbiMed Private Investments VII, LP (\"OPI VII\"). OrbiMed Capital GP VII LLC (\"GP VII\") is the general partner of OPI VII and OrbiMed Advisors LLC (\"OrbiMed Advisors\") is the managing member of GP VII. By virtue of such relationships, GP VII and OrbiMed Advisors may be deemed to have voting and investment power over the securities held by OPI VII and as a result may be deemed to have beneficial ownership over such securities. The Reporting Person is an employee of OrbiMed Advisors. OrbiMed Advisors exercises its investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and Jonathan T. Silverstein, each of whom disclaims beneficial ownership of the securities held by OPI VII."}],"balance_after":148395,"derivative":{"underlying":"Common Shares","underlying_shares":385782},"source":{"system":"sec-edgar","filing":"0000899243-20-030411","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1609405/000089924320030411/doc4.xml","form_type":"4"}},{"id":2992205,"issuer":{"id":4602,"kind":"organization","name":"Damora Therapeutics, Inc.","symbol":"DMRA"},"owners":[{"id":111954,"kind":"person","name":"Khuong Chau Quang","position":1,"cik":"0001609405","reported_name":"Khuong Chau Quang","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Shares","published_at":"2020-11-04T20:00:11.000Z","date":"2020-11-02","kind":"purchase","acquired":true,"shares":209500,"price":15,"value":3142500.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These securities are held of record by OrbiMed Israel Partners II, L.P. (\"OIP II\"). OrbiMed Israel is the general partner of OIP II, and OrbiMed Limited is the managing member of OrbiMed Israel. By virtue of such relationships, OrbiMed Israel and OrbiMed Limited may be deemed to have voting and investment power over the securities held by OIP II and as a result may be deemed to have beneficial ownership over such securities. OrbiMed Limited exercises its investment and voting power through a management committee comprised of Carl L. Gordon, Jonathan Silverstein, Nissim Darvish, Anat Naschitz, and Erez Chimovits, each of whom disclaims beneficial ownership of the securities held by OIP II."}],"balance_after":1031811,"source":{"system":"sec-edgar","filing":"0000899243-20-030411","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1609405/000089924320030411/doc4.xml","form_type":"4"}},{"id":2992204,"issuer":{"id":4602,"kind":"organization","name":"Damora Therapeutics, Inc.","symbol":"DMRA"},"owners":[{"id":111954,"kind":"person","name":"Khuong Chau Quang","position":1,"cik":"0001609405","reported_name":"Khuong Chau Quang","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Shares","published_at":"2020-11-04T20:00:11.000Z","date":"2020-11-02","kind":"purchase","acquired":true,"shares":523833,"price":15,"value":7857495.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held of record by OrbiMed Private Investments VII, LP (\"OPI VII\"). OrbiMed Capital GP VII LLC (\"GP VII\") is the general partner of OPI VII and OrbiMed Advisors LLC (\"OrbiMed Advisors\") is the managing member of GP VII. By virtue of such relationships, GP VII and OrbiMed Advisors may be deemed to have voting and investment power over the securities held by OPI VII and as a result may be deemed to have beneficial ownership over such securities. The Reporting Person is an employee of OrbiMed Advisors. OrbiMed Advisors exercises its investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and Jonathan T. Silverstein, each of whom disclaims beneficial ownership of the securities held by OPI VII."}],"balance_after":2579657,"source":{"system":"sec-edgar","filing":"0000899243-20-030411","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1609405/000089924320030411/doc4.xml","form_type":"4"}},{"id":2992203,"issuer":{"id":4602,"kind":"organization","name":"Damora Therapeutics, Inc.","symbol":"DMRA"},"owners":[{"id":111954,"kind":"person","name":"Khuong Chau Quang","position":1,"cik":"0001609405","reported_name":"Khuong Chau Quang","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Shares","published_at":"2020-11-04T20:00:11.000Z","date":"2020-11-02","kind":"exercise","acquired":true,"shares":191787,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The Series C-2 Preferred Stock, Series C-4 Preferred Stock, Series C-5 Preferred Stock, and Series D Preferred Stock (collectively, the \"Preferred Stock\") was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock converted into Common Stock at a ratio of 2.59970:1 upon the closing of the Issuer's initial public offering without payment of additional consideration. The Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"These securities are held of record by OrbiMed Genesis Master Fund, L.P. (\"Genesis Master Fund\"). OrbiMed Genesis GP LLC (\"Genesis GP\") is the general partner of Genesis Master Fund and OrbiMed Advisors is the managing member of Genesis GP. By virtue of such relationships, Genesis GP and OrbiMed Advisors may be deemed to have voting and investment power over the securities held by Genesis Master Fund and as a result may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises its investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and Jonathan T. Silverstein, each of whom disclaims beneficial ownership of the securities held by Genesis Master Fund."}],"balance_after":191787,"source":{"system":"sec-edgar","filing":"0000899243-20-030411","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1609405/000089924320030411/doc4.xml","form_type":"4"}},{"id":2992202,"issuer":{"id":4602,"kind":"organization","name":"Damora Therapeutics, Inc.","symbol":"DMRA"},"owners":[{"id":111954,"kind":"person","name":"Khuong Chau Quang","position":1,"cik":"0001609405","reported_name":"Khuong Chau Quang","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Shares","published_at":"2020-11-04T20:00:11.000Z","date":"2020-11-02","kind":"exercise","acquired":true,"shares":822311,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The Series C-2 Preferred Stock, Series C-4 Preferred Stock, Series C-5 Preferred Stock, and Series D Preferred Stock (collectively, the \"Preferred Stock\") was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock converted into Common Stock at a ratio of 2.59970:1 upon the closing of the Issuer's initial public offering without payment of additional consideration. The Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These securities are held of record by OrbiMed Israel Partners II, L.P. (\"OIP II\"). OrbiMed Israel is the general partner of OIP II, and OrbiMed Limited is the managing member of OrbiMed Israel. By virtue of such relationships, OrbiMed Israel and OrbiMed Limited may be deemed to have voting and investment power over the securities held by OIP II and as a result may be deemed to have beneficial ownership over such securities. OrbiMed Limited exercises its investment and voting power through a management committee comprised of Carl L. Gordon, Jonathan Silverstein, Nissim Darvish, Anat Naschitz, and Erez Chimovits, each of whom disclaims beneficial ownership of the securities held by OIP II."}],"balance_after":822311,"source":{"system":"sec-edgar","filing":"0000899243-20-030411","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1609405/000089924320030411/doc4.xml","form_type":"4"}},{"id":2992201,"issuer":{"id":4602,"kind":"organization","name":"Damora Therapeutics, Inc.","symbol":"DMRA"},"owners":[{"id":111954,"kind":"person","name":"Khuong Chau Quang","position":1,"cik":"0001609405","reported_name":"Khuong Chau Quang","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Shares","published_at":"2020-11-04T20:00:11.000Z","date":"2020-11-02","kind":"exercise","acquired":true,"shares":2055824,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The Series C-2 Preferred Stock, Series C-4 Preferred Stock, Series C-5 Preferred Stock, and Series D Preferred Stock (collectively, the \"Preferred Stock\") was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock converted into Common Stock at a ratio of 2.59970:1 upon the closing of the Issuer's initial public offering without payment of additional consideration. The Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held of record by OrbiMed Private Investments VII, LP (\"OPI VII\"). OrbiMed Capital GP VII LLC (\"GP VII\") is the general partner of OPI VII and OrbiMed Advisors LLC (\"OrbiMed Advisors\") is the managing member of GP VII. By virtue of such relationships, GP VII and OrbiMed Advisors may be deemed to have voting and investment power over the securities held by OPI VII and as a result may be deemed to have beneficial ownership over such securities. The Reporting Person is an employee of OrbiMed Advisors. OrbiMed Advisors exercises its investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and Jonathan T. Silverstein, each of whom disclaims beneficial ownership of the securities held by OPI VII."}],"balance_after":2055824,"source":{"system":"sec-edgar","filing":"0000899243-20-030411","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1609405/000089924320030411/doc4.xml","form_type":"4"}},{"id":3008256,"issuer":{"id":1186,"kind":"organization","name":"Inspire Medical Systems, Inc.","symbol":"INSP"},"owners":[{"id":111954,"kind":"person","name":"Khuong Chau Quang","position":1,"cik":"0001609405","reported_name":"Khuong Chau Quang","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-10-13T20:16:55.000Z","date":"2020-10-09","kind":"grant","acquired":true,"shares":91,"price":130,"value":11830.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of common stock received in lieu of cash fees pursuant to the Issuer's Non-Employee Director Compensation Policy."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Pursuant to an agreement with OrbiMed Advisors LLC (\"Advisors\") and OrbiMed Capital GP V LLC (\"GP V\"), the Reporting Person is obligated to transfer these securities, or the economic benefit thereof, to Advisors and GP V, which will in turn ensure that such securities or economic benefits are provided to OrbiMed Private Investments V, LP (\"OPI V\")."}],"balance_after":1875,"source":{"system":"sec-edgar","filing":"0001104659-20-114515","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1609550/000110465920114515/a4.xml","form_type":"4"}},{"id":3052358,"issuer":{"id":1186,"kind":"organization","name":"Inspire Medical Systems, Inc.","symbol":"INSP"},"owners":[{"id":111954,"kind":"person","name":"Khuong Chau Quang","position":1,"cik":"0001609405","reported_name":"Khuong Chau Quang","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock, $0.001 par value","published_at":"2020-08-19T21:19:26.000Z","date":"2020-08-18","kind":"sale","acquired":false,"shares":43543,"price":108.54,"value":4726157.22,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"These shares of the Issuer's common stock were sold in a block order at a price of $108.54."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares of the Issuer's common stock are held of record by OrbiMed Private Investments V, LP (\"OPI V\"). OrbiMed Capital GP V LLC (\"GP V\") is the general partner of OPI V, and OrbiMed Advisors LLC (\"Advisors\"), a registered investment adviser under the Investment Advisors Act of 1940, as amended, is the managing member of GP V. By virtue of such relationships, GP V and Advisors may be deemed to have voting and investment power with respect to the securities held by OPI V noted above and as a result may be deemed to beneficially own such securities for purposes of Rule 13d-3 under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"). Advisors exercises this investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho and Jonathan T. Silverstein, each of whom disclaims beneficial ownership of the Shares held by OPI V. The Reporting Person is an employee of Advisors."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Each of the Reporting Person, GP V and Advisors disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Exchange Act, except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Person, GP V or Advisors is a beneficial owner of such securities for the purposes of Section 16 of the Exchange Act, or for any other purposes."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000947871-20-000698","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1609550/000094787120000698/ownership.xml","form_type":"4"}},{"id":3052357,"issuer":{"id":1186,"kind":"organization","name":"Inspire Medical Systems, Inc.","symbol":"INSP"},"owners":[{"id":111954,"kind":"person","name":"Khuong Chau Quang","position":1,"cik":"0001609405","reported_name":"Khuong Chau Quang","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock, $0.001 par value","published_at":"2020-08-19T21:19:26.000Z","date":"2020-08-17","kind":"sale","acquired":false,"shares":94900,"price":107.49,"value":10200801.0,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"These shares of the Issuer's common stock were sold in a block order at a price of $107.49."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares of the Issuer's common stock are held of record by OrbiMed Private Investments V, LP (\"OPI V\"). OrbiMed Capital GP V LLC (\"GP V\") is the general partner of OPI V, and OrbiMed Advisors LLC (\"Advisors\"), a registered investment adviser under the Investment Advisors Act of 1940, as amended, is the managing member of GP V. By virtue of such relationships, GP V and Advisors may be deemed to have voting and investment power with respect to the securities held by OPI V noted above and as a result may be deemed to beneficially own such securities for purposes of Rule 13d-3 under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"). Advisors exercises this investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho and Jonathan T. Silverstein, each of whom disclaims beneficial ownership of the Shares held by OPI V. The Reporting Person is an employee of Advisors."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Each of the Reporting Person, GP V and Advisors disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Exchange Act, except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Person, GP V or Advisors is a beneficial owner of such securities for the purposes of Section 16 of the Exchange Act, or for any other purposes."}],"balance_after":43543,"source":{"system":"sec-edgar","filing":"0000947871-20-000698","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1609550/000094787120000698/ownership.xml","form_type":"4"}},{"id":3057283,"issuer":{"id":1186,"kind":"organization","name":"Inspire Medical Systems, Inc.","symbol":"INSP"},"owners":[{"id":111954,"kind":"person","name":"Khuong Chau Quang","position":1,"cik":"0001609405","reported_name":"Khuong Chau Quang","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock, $0.001 par value","published_at":"2020-08-14T21:22:24.000Z","date":"2020-08-14","kind":"sale","acquired":false,"shares":20237,"price":109.03,"value":2206440.11,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"These shares of the Issuer's common stock were sold in a block order at a price of $109.03."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares of the Issuer's common stock are held of record by OrbiMed Private Investments V, LP (\"OPI V\"). OrbiMed Capital GP V LLC (\"GP V\") is the general partner of OPI V, and OrbiMed Advisors LLC (\"Advisors\"), a registered investment adviser under the Investment Advisors Act of 1940, as amended, is the managing member of GP V. By virtue of such relationships, GP V and Advisors may be deemed to have voting and investment power with respect to the securities held by OPI V noted above and as a result may be deemed to beneficially own such securities for purposes of Rule 13d-3 under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"). Advisors exercises this investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho and Jonathan T. Silverstein, each of whom disclaims beneficial ownership of the Shares held by OPI V. The Reporting Person is an employee of Advisors."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Each of the Reporting Person, GP V and Advisors disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Exchange Act, except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Person, GP V or Advisors is a beneficial owner of such securities for the purposes of Section 16 of the Exchange Act, or for any other purposes."}],"balance_after":138443,"source":{"system":"sec-edgar","filing":"0000947871-20-000685","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1609550/000094787120000685/ownership.xml","form_type":"4"}},{"id":3057282,"issuer":{"id":1186,"kind":"organization","name":"Inspire Medical Systems, Inc.","symbol":"INSP"},"owners":[{"id":111954,"kind":"person","name":"Khuong Chau Quang","position":1,"cik":"0001609405","reported_name":"Khuong Chau Quang","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock, $0.001 par value","published_at":"2020-08-14T21:22:24.000Z","date":"2020-08-13","kind":"sale","acquired":false,"shares":29251,"price":109.93,"value":3215562.43,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"These shares of the Issuer's common stock were sold in a block order at a price of $109.93."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares of the Issuer's common stock are held of record by OrbiMed Private Investments V, LP (\"OPI V\"). OrbiMed Capital GP V LLC (\"GP V\") is the general partner of OPI V, and OrbiMed Advisors LLC (\"Advisors\"), a registered investment adviser under the Investment Advisors Act of 1940, as amended, is the managing member of GP V. By virtue of such relationships, GP V and Advisors may be deemed to have voting and investment power with respect to the securities held by OPI V noted above and as a result may be deemed to beneficially own such securities for purposes of Rule 13d-3 under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"). Advisors exercises this investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho and Jonathan T. Silverstein, each of whom disclaims beneficial ownership of the Shares held by OPI V. The Reporting Person is an employee of Advisors."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Each of the Reporting Person, GP V and Advisors disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Exchange Act, except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Person, GP V or Advisors is a beneficial owner of such securities for the purposes of Section 16 of the Exchange Act, or for any other purposes."}],"balance_after":158500,"source":{"system":"sec-edgar","filing":"0000947871-20-000685","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1609550/000094787120000685/ownership.xml","form_type":"4"}},{"id":3057281,"issuer":{"id":1186,"kind":"organization","name":"Inspire Medical Systems, Inc.","symbol":"INSP"},"owners":[{"id":111954,"kind":"person","name":"Khuong Chau Quang","position":1,"cik":"0001609405","reported_name":"Khuong Chau Quang","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock, $0.001 par value","published_at":"2020-08-14T21:22:24.000Z","date":"2020-08-12","kind":"sale","acquired":false,"shares":42679,"price":107.45,"value":4585858.55,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"These shares of the Issuer's common stock were sold in a block order at a price of $107.45."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares of the Issuer's common stock are held of record by OrbiMed Private Investments V, LP (\"OPI V\"). OrbiMed Capital GP V LLC (\"GP V\") is the general partner of OPI V, and OrbiMed Advisors LLC (\"Advisors\"), a registered investment adviser under the Investment Advisors Act of 1940, as amended, is the managing member of GP V. By virtue of such relationships, GP V and Advisors may be deemed to have voting and investment power with respect to the securities held by OPI V noted above and as a result may be deemed to beneficially own such securities for purposes of Rule 13d-3 under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"). Advisors exercises this investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho and Jonathan T. Silverstein, each of whom disclaims beneficial ownership of the Shares held by OPI V. The Reporting Person is an employee of Advisors."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Each of the Reporting Person, GP V and Advisors disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Exchange Act, except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Person, GP V or Advisors is a beneficial owner of such securities for the purposes of Section 16 of the Exchange Act, or for any other purposes."}],"balance_after":187751,"source":{"system":"sec-edgar","filing":"0000947871-20-000685","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1609550/000094787120000685/ownership.xml","form_type":"4"}},{"id":3061849,"issuer":{"id":1186,"kind":"organization","name":"Inspire Medical Systems, Inc.","symbol":"INSP"},"owners":[{"id":111954,"kind":"person","name":"Khuong Chau Quang","position":1,"cik":"0001609405","reported_name":"Khuong Chau Quang","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock, $0.001 par value","published_at":"2020-08-11T22:19:59.000Z","date":"2020-08-11","kind":"sale","acquired":false,"shares":39877,"price":105.78,"value":4218189.06,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"These shares of the Issuer's common stock were sold in a block order at a price of $105.78."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares of the Issuer's common stock are held of record by OrbiMed Private Investments V, LP (\"OPI V\"). OrbiMed Capital GP V LLC (\"GP V\") is the general partner of OPI V, and OrbiMed Advisors LLC (\"Advisors\"), a registered investment adviser under the Investment Advisors Act of 1940, as amended, is the managing member of GP V. By virtue of such relationships, GP V and Advisors may be deemed to have voting and investment power with respect to the securities held by OPI V noted above and as a result may be deemed to beneficially own such securities for purposes of Rule 13d-3 under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"). Advisors exercises this investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho and Jonathan T. Silverstein, each of whom disclaims beneficial ownership of the Shares held by OPI V. The Reporting Person is an employee of Advisors."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Each of the Reporting Person, GP V and Advisors disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Exchange Act, except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Person, GP V or Advisors is a beneficial owner of such securities for the purposes of Section 16 of the Exchange Act, or for any other purposes."}],"balance_after":230430,"source":{"system":"sec-edgar","filing":"0000947871-20-000675","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1609550/000094787120000675/ownership.xml","form_type":"4"}},{"id":3061848,"issuer":{"id":1186,"kind":"organization","name":"Inspire Medical Systems, Inc.","symbol":"INSP"},"owners":[{"id":111954,"kind":"person","name":"Khuong Chau Quang","position":1,"cik":"0001609405","reported_name":"Khuong Chau Quang","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock, $0.001 par value","published_at":"2020-08-11T22:19:59.000Z","date":"2020-08-10","kind":"sale","acquired":false,"shares":47700,"price":105.23,"value":5019471.0,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"These shares of the Issuer's common stock were sold in two separate block orders, each at a price of $105.23."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares of the Issuer's common stock are held of record by OrbiMed Private Investments V, LP (\"OPI V\"). OrbiMed Capital GP V LLC (\"GP V\") is the general partner of OPI V, and OrbiMed Advisors LLC (\"Advisors\"), a registered investment adviser under the Investment Advisors Act of 1940, as amended, is the managing member of GP V. By virtue of such relationships, GP V and Advisors may be deemed to have voting and investment power with respect to the securities held by OPI V noted above and as a result may be deemed to beneficially own such securities for purposes of Rule 13d-3 under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"). Advisors exercises this investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho and Jonathan T. Silverstein, each of whom disclaims beneficial ownership of the Shares held by OPI V. The Reporting Person is an employee of Advisors."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Each of the Reporting Person, GP V and Advisors disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Exchange Act, except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Person, GP V or Advisors is a beneficial owner of such securities for the purposes of Section 16 of the Exchange Act, or for any other purposes."}],"balance_after":270307,"source":{"system":"sec-edgar","filing":"0000947871-20-000675","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1609550/000094787120000675/ownership.xml","form_type":"4"}},{"id":3061847,"issuer":{"id":1186,"kind":"organization","name":"Inspire Medical Systems, Inc.","symbol":"INSP"},"owners":[{"id":111954,"kind":"person","name":"Khuong Chau Quang","position":1,"cik":"0001609405","reported_name":"Khuong Chau Quang","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock, $0.001 par value","published_at":"2020-08-11T22:19:59.000Z","date":"2020-08-07","kind":"sale","acquired":false,"shares":28993,"price":106.18,"value":3078476.74,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"These shares of the Issuer's common stock were sold in a block order at a price of $106.18."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares of the Issuer's common stock are held of record by OrbiMed Private Investments V, LP (\"OPI V\"). OrbiMed Capital GP V LLC (\"GP V\") is the general partner of OPI V, and OrbiMed Advisors LLC (\"Advisors\"), a registered investment adviser under the Investment Advisors Act of 1940, as amended, is the managing member of GP V. By virtue of such relationships, GP V and Advisors may be deemed to have voting and investment power with respect to the securities held by OPI V noted above and as a result may be deemed to beneficially own such securities for purposes of Rule 13d-3 under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"). Advisors exercises this investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho and Jonathan T. Silverstein, each of whom disclaims beneficial ownership of the Shares held by OPI V. The Reporting Person is an employee of Advisors."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Each of the Reporting Person, GP V and Advisors disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Exchange Act, except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Person, GP V or Advisors is a beneficial owner of such securities for the purposes of Section 16 of the Exchange Act, or for any other purposes."}],"balance_after":318007,"source":{"system":"sec-edgar","filing":"0000947871-20-000675","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1609550/000094787120000675/ownership.xml","form_type":"4"}},{"id":3083581,"issuer":{"id":1186,"kind":"organization","name":"Inspire Medical Systems, Inc.","symbol":"INSP"},"owners":[{"id":111954,"kind":"person","name":"Khuong Chau Quang","position":1,"cik":"0001609405","reported_name":"Khuong Chau Quang","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-07-14T20:37:37.000Z","date":"2020-07-10","kind":"grant","acquired":true,"shares":128,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of common stock received in lieu of cash fees pursuant to the Issuer's Non-Employee Director Compensation Policy."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Pursuant to an agreement with OrbiMed Advisors LLC (\"Advisors\") and OrbiMed Capital GP V LLC (\"GP V\"), the Reporting Person is obligated to transfer these securities, or the economic benefit thereof, to Advisors and GP V, which will in turn ensure that such securities or economic benefits are provided to OrbiMed Private Investments V, LP (\"OPI V\")."}],"balance_after":1784,"source":{"system":"sec-edgar","filing":"0001104659-20-083450","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1609550/000110465920083450/a4.xml","form_type":"4"}},{"id":3092441,"issuer":{"id":11851,"kind":"organization","name":"Fusion Pharmaceuticals Inc.","symbol":"FUSN"},"owners":[{"id":111954,"kind":"person","name":"Khuong Chau Quang","position":1,"cik":"0001609405","reported_name":"Khuong Chau Quang","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class B Preferred Shares","published_at":"2020-07-02T16:03:12.000Z","date":"2020-06-30","kind":"exercise","acquired":false,"shares":11878051,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The Class B Preferred Shares were convertible into Common Shares on a one-for-5.339 basis. Upon the closing of the Issuer's initial public offering, all Class B Preferred Shares converted into Common Shares."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The Class B Preferred Shares were convertible into Common Shares on a one-for-5.339 basis. Upon the closing of the Issuer's initial public offering, all Class B Preferred Shares converted into Common Shares."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Class B Preferred Shares were convertible into Common Shares on a one-for-5.339 basis. Upon the closing of the Issuer's initial public offering, all Class B Preferred Shares converted into Common Shares."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The Class B Preferred Shares were convertible into Common Shares on a one-for-5.339 basis. Upon the closing of the Issuer's initial public offering, all Class B Preferred Shares converted into Common Shares."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"OrbiMed Capital GP VII LLC (\"GP VII\") is the general partner of OrbiMed Private Investments VII, LP (\"OPI VII\"). OrbiMed Advisors LLC (\"OrbiMed Advisors\") is the managing member of GP VII. By virtue of such relationships, GP VII and OrbiMed Advisors may be deemed to have voting and investment power with respect to the shares held by OPI VII and as a result may be deemed to have beneficial ownership of such shares. The Reporting Person is an employee of OrbiMed Advisors. OrbiMed Capital LLC (\"OrbiMed Capital\") is a relying advisor of OrbiMed Advisors. OrbiMed Capital and OrbiMed Advisors exercise investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho and Jonathan T. Silverstein. Each of OrbiMed Capital, GP VII, OrbiMed Advisors, and the Reporting Person disclaims beneficial ownership of the shares held by OPI VII, except to the extent of its or his pecuniary interest therein, if any."}],"balance_after":0,"derivative":{"underlying":"Common Shares","underlying_shares":2224770},"source":{"system":"sec-edgar","filing":"0000899243-20-018258","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1805890/000089924320018258/doc4.xml","form_type":"4"}},{"id":3092440,"issuer":{"id":11851,"kind":"organization","name":"Fusion Pharmaceuticals Inc.","symbol":"FUSN"},"owners":[{"id":111954,"kind":"person","name":"Khuong Chau Quang","position":1,"cik":"0001609405","reported_name":"Khuong Chau Quang","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2020-07-02T16:03:12.000Z","date":"2020-06-30","kind":"purchase","acquired":true,"shares":192100,"price":17,"value":3265700.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"OrbiMed Capital is the investment advisor to OrbiMed Partners Master Fund Limited (\"OPM\"). OrbiMed Capital is a relying advisor of OrbiMed Advisors. OrbiMed Advisors and OrbiMed Capital exercise investment and voting power through a management committee comprised of Carl L. Gordon, Jonathan T. Silverstein, and Sven H. Borho, each of whom disclaims beneficial ownership of the shares of OPM."}],"balance_after":192100,"source":{"system":"sec-edgar","filing":"0000899243-20-018258","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1805890/000089924320018258/doc4.xml","form_type":"4"}},{"id":3092439,"issuer":{"id":11851,"kind":"organization","name":"Fusion Pharmaceuticals Inc.","symbol":"FUSN"},"owners":[{"id":111954,"kind":"person","name":"Khuong Chau Quang","position":1,"cik":"0001609405","reported_name":"Khuong Chau Quang","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2020-07-02T16:03:12.000Z","date":"2020-06-30","kind":"purchase","acquired":true,"shares":705900,"price":17,"value":12000300.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"OrbiMed Capital GP VII LLC (\"GP VII\") is the general partner of OrbiMed Private Investments VII, LP (\"OPI VII\"). OrbiMed Advisors LLC (\"OrbiMed Advisors\") is the managing member of GP VII. By virtue of such relationships, GP VII and OrbiMed Advisors may be deemed to have voting and investment power with respect to the shares held by OPI VII and as a result may be deemed to have beneficial ownership of such shares. The Reporting Person is an employee of OrbiMed Advisors. OrbiMed Capital LLC (\"OrbiMed Capital\") is a relying advisor of OrbiMed Advisors. OrbiMed Capital and OrbiMed Advisors exercise investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho and Jonathan T. Silverstein. Each of OrbiMed Capital, GP VII, OrbiMed Advisors, and the Reporting Person disclaims beneficial ownership of the shares held by OPI VII, except to the extent of its or his pecuniary interest therein, if any."}],"balance_after":2930670,"source":{"system":"sec-edgar","filing":"0000899243-20-018258","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1805890/000089924320018258/doc4.xml","form_type":"4"}},{"id":3092438,"issuer":{"id":11851,"kind":"organization","name":"Fusion Pharmaceuticals Inc.","symbol":"FUSN"},"owners":[{"id":111954,"kind":"person","name":"Khuong Chau Quang","position":1,"cik":"0001609405","reported_name":"Khuong Chau Quang","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2020-07-02T16:03:12.000Z","date":"2020-06-30","kind":"exercise","acquired":true,"shares":2224770,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The Class B Preferred Shares were convertible into Common Shares on a one-for-5.339 basis. Upon the closing of the Issuer's initial public offering, all Class B Preferred Shares converted into Common Shares."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"OrbiMed Capital GP VII LLC (\"GP VII\") is the general partner of OrbiMed Private Investments VII, LP (\"OPI VII\"). OrbiMed Advisors LLC (\"OrbiMed Advisors\") is the managing member of GP VII. By virtue of such relationships, GP VII and OrbiMed Advisors may be deemed to have voting and investment power with respect to the shares held by OPI VII and as a result may be deemed to have beneficial ownership of such shares. The Reporting Person is an employee of OrbiMed Advisors. OrbiMed Capital LLC (\"OrbiMed Capital\") is a relying advisor of OrbiMed Advisors. OrbiMed Capital and OrbiMed Advisors exercise investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho and Jonathan T. Silverstein. Each of OrbiMed Capital, GP VII, OrbiMed Advisors, and the Reporting Person disclaims beneficial ownership of the shares held by OPI VII, except to the extent of its or his pecuniary interest therein, if any."}],"balance_after":2224770,"source":{"system":"sec-edgar","filing":"0000899243-20-018258","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1805890/000089924320018258/doc4.xml","form_type":"4"}},{"id":3096766,"issuer":{"id":11851,"kind":"organization","name":"Fusion Pharmaceuticals Inc.","symbol":"FUSN"},"owners":[{"id":111954,"kind":"person","name":"Khuong Chau Quang","position":1,"cik":"0001609405","reported_name":"Khuong Chau Quang","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-06-30T06:41:20.000Z","date":"2020-06-25","kind":"grant","acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"This option shall vest and become exercisable in 36 equal monthly installments commencing on July 18, 2020."}],"balance_after":30000,"derivative":{"exercise_price":17,"expiration_date":"2030-06-18","underlying":"Common Shares","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0000899243-20-017877","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1805890/000089924320017877/doc4.xml","form_type":"4"}},{"id":3096765,"issuer":{"id":11851,"kind":"organization","name":"Fusion Pharmaceuticals Inc.","symbol":"FUSN"},"owners":[{"id":111954,"kind":"person","name":"Khuong Chau Quang","position":1,"cik":"0001609405","reported_name":"Khuong Chau Quang","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class B Preferred Shares","published_at":"2020-06-30T06:41:20.000Z","date":"2020-06-02","kind":"purchase","acquired":true,"shares":5939025,"price":1.1514,"value":6838193.385,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"The Class B Preferred Shares are convertible into Common Shares on a one-for-5.339 basis. Upon the closing of the Issuer's initial public offering, the Class B Preferred Shares will convert into the number of Common Shares shown in column 7. The Class B Preferred Shares have no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The Class B Preferred Shares are convertible into Common Shares on a one-for-5.339 basis. Upon the closing of the Issuer's initial public offering, the Class B Preferred Shares will convert into the number of Common Shares shown in column 7. The Class B Preferred Shares have no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The Class B Preferred Shares are convertible into Common Shares on a one-for-5.339 basis. Upon the closing of the Issuer's initial public offering, the Class B Preferred Shares will convert into the number of Common Shares shown in column 7. The Class B Preferred Shares have no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"OrbiMed Capital GP VII LLC (\"GP VII\") is the general partner of OrbiMed Private Investments VII, LP (\"OPI VII\"). OrbiMed Advisors LLC (\"OrbiMed Advisors\") is the managing member of GP VII. By virtue of such relationships, GP VII and OrbiMed Advisors may be deemed to have voting and investment power with respect to the shares held by OPI VII and as a result may be deemed to have beneficial ownership of such shares. The Reporting Person is an employee of OrbiMed Advisors. OrbiMed Advisors exercises investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho and Jonathan T. Silverstein. Each of GP VII, OrbiMed Advisors and the Reporting Person disclaims beneficial ownership of the shares held by OPI VII, except to the extent of its or his pecuniary interest therein, if any."}],"balance_after":11878051,"derivative":{"underlying":"Common Shares","underlying_shares":1112385},"source":{"system":"sec-edgar","filing":"0000899243-20-017877","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1805890/000089924320017877/doc4.xml","form_type":"4"}},{"id":3096764,"issuer":{"id":11851,"kind":"organization","name":"Fusion Pharmaceuticals Inc.","symbol":"FUSN"},"owners":[{"id":111954,"kind":"person","name":"Khuong Chau Quang","position":1,"cik":"0001609405","reported_name":"Khuong Chau Quang","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Warrants to Purchase Class B Preferred Shares","published_at":"2020-06-30T06:41:20.000Z","date":"2020-01-10","kind":"grant","acquired":true,"shares":359377,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Upon the closing of the Issuer's initial public offering, the Warrants to purchase Class B Preferred Shares will become warrants to purchase Common Shares at an exercise price of $8.10 per share."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Upon the closing of the Issuer's initial public offering, the Warrants to purchase Class B Preferred Shares will become warrants to purchase Common Shares at an exercise price of $8.10 per share."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Upon the closing of the Issuer's initial public offering, the Warrants to purchase Class B Preferred Shares will become warrants to purchase Common Shares at an exercise price of $8.10 per share."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"OrbiMed Capital GP VII LLC (\"GP VII\") is the general partner of OrbiMed Private Investments VII, LP (\"OPI VII\"). OrbiMed Advisors LLC (\"OrbiMed Advisors\") is the managing member of GP VII. By virtue of such relationships, GP VII and OrbiMed Advisors may be deemed to have voting and investment power with respect to the shares held by OPI VII and as a result may be deemed to have beneficial ownership of such shares. The Reporting Person is an employee of OrbiMed Advisors. OrbiMed Advisors exercises investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho and Jonathan T. Silverstein. Each of GP VII, OrbiMed Advisors and the Reporting Person disclaims beneficial ownership of the shares held by OPI VII, except to the extent of its or his pecuniary interest therein, if any."}],"balance_after":359377,"derivative":{"exercise_price":1.1514,"exercise_date":"2020-01-10","expiration_date":"2022-01-10","underlying":"Common Shares","underlying_shares":67311},"source":{"system":"sec-edgar","filing":"0000899243-20-017877","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1805890/000089924320017877/doc4.xml","form_type":"4"}},{"id":3110071,"issuer":{"id":7461,"kind":"organization","name":"NextCure, Inc."},"owners":[{"id":111954,"kind":"person","name":"Khuong Chau Quang","position":1,"cik":"0001609405","reported_name":"Khuong Chau Quang","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-06-15T17:42:20.000Z","date":"2020-06-11","kind":"grant","acquired":true,"shares":14250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests in full on the earlier of June 11, 2021 and the date of the 2021 Annual Meeting of Stockholders."}],"balance_after":14250,"derivative":{"exercise_price":24.13,"expiration_date":"2030-06-10","underlying":"Common Stock","underlying_shares":14250},"source":{"system":"sec-edgar","filing":"0001123292-20-000881","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1609405/000112329220000881/edgar.xml","form_type":"4"}},{"id":3118167,"issuer":{"id":7801,"kind":"organization","name":"SYNLOGIC, INC."},"owners":[{"id":111954,"kind":"person","name":"Khuong Chau Quang","position":1,"cik":"0001609405","reported_name":"Khuong Chau Quang","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2020-06-08T21:32:31.000Z","date":"2020-06-04","kind":"grant","acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests and becomes exercisable in full on the earlier of (A) the first anniversary of the date of grant or (B) immediately prior to the next annual meeting of the Corporation's stockholders after the date of grant, subject to the non-employee director's continued service as a director of the Corporation."}],"balance_after":15000,"derivative":{"exercise_price":2.22,"expiration_date":"2030-06-04","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0000899243-20-015649","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1527599/000089924320015649/doc4.xml","form_type":"4"}},{"id":3163657,"issuer":{"id":1186,"kind":"organization","name":"Inspire Medical Systems, Inc.","symbol":"INSP"},"owners":[{"id":111954,"kind":"person","name":"Khuong Chau Quang","position":1,"cik":"0001609405","reported_name":"Khuong Chau Quang","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2020-05-05T00:39:09.000Z","date":"2020-04-30","kind":"grant","acquired":true,"shares":3501,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests and becomes exercisable on April 30, 2021, subject to the Reporting Person's continuous service to the Issuer through such date."}],"balance_after":3501,"derivative":{"exercise_price":71.66,"expiration_date":"2030-04-30","underlying":"Common Stock","underlying_shares":3501},"source":{"system":"sec-edgar","filing":"0001104659-20-056420","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1609550/000110465920056420/a4.xml","form_type":"4"}},{"id":3177184,"issuer":{"id":1186,"kind":"organization","name":"Inspire Medical Systems, Inc.","symbol":"INSP"},"owners":[{"id":111954,"kind":"person","name":"Khuong Chau Quang","position":1,"cik":"0001609405","reported_name":"Khuong Chau Quang","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-04-14T21:54:17.000Z","date":"2020-04-10","kind":"grant","acquired":true,"shares":183,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of common stock received in lieu of cash fees pursuant to the Issuer's Non-Employee Director Compensation Policy."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Pursuant to an agreement with OrbiMed Advisors LLC (\"Advisors\") and OrbiMed Capital GP V LLC (\"GP V\"), the Reporting Person is obligated to transfer these securities, or the economic benefit thereof, to Advisors and GP V, which will in turn ensure that such securities or economic benefits are provided to OrbiMed Private Investments V, LP (\"OPI V\")."}],"balance_after":1656,"source":{"system":"sec-edgar","filing":"0001104659-20-046463","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1609550/000110465920046463/a4.xml","form_type":"4"}},{"id":3217801,"issuer":{"id":1186,"kind":"organization","name":"Inspire Medical Systems, Inc.","symbol":"INSP"},"owners":[{"id":111954,"kind":"person","name":"Khuong Chau Quang","position":1,"cik":"0001609405","reported_name":"Khuong Chau Quang","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock, $0.001 par value","published_at":"2020-03-10T21:08:38.000Z","date":"2020-03-06","kind":"sale","acquired":false,"shares":500000,"price":83.52,"value":41760000.0,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"These shares of the Issuer's common stock were sold in two separate block orders, each at a price of $83.52."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares of the Issuer's common stock are held of record by OPI V. OrbiMed Capital GP V LLC (\"GP V\") is the sole general partner of OPI V, and OrbiMed Advisors LLC (\"Advisors\"), a registered adviser under the Investment Advisors Act of 1940, as amended, is the sole managing member of GP V. By virtue of such relationships, GP V and Advisors may be deemed to have voting and investment power with respect to the securities held by OPI V noted above and as a result may be deemed to beneficially own such securities for purposes of Rule 13d-3 under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"). Advisors exercised this investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho and Jonathan T. Silverstein, each of whom disclaims beneficial ownership of the Shares held by OPI V. The Reporting Person is an employee of Advisors."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Each of the Reporting Person, GP V and Advisors disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Exchange Act, except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Person, GP V or Advisors is a beneficial owner of such securities for the purposes of Section 16 of the Exchange Act, or for any other purposes."}],"balance_after":347000,"source":{"system":"sec-edgar","filing":"0000947871-20-000209","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1609550/000094787120000209/ownership.xml","form_type":"4"}},{"id":3224549,"issuer":{"id":1186,"kind":"organization","name":"Inspire Medical Systems, Inc.","symbol":"INSP"},"owners":[{"id":111954,"kind":"person","name":"Khuong Chau Quang","position":1,"cik":"0001609405","reported_name":"Khuong Chau Quang","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock, $0.001 par value","published_at":"2020-03-05T23:37:16.000Z","date":"2020-03-04","kind":"sale","acquired":false,"shares":400000,"price":84.42,"value":33768000.0,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"These shares of the Issuer's common stock were sold in a block order at a price of $84.42."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares of the Issuer's common stock are held of record by OPI V. OrbiMed Capital GP V LLC (\"GP V\") is the sole general partner of OPI V, and OrbiMed Advisors LLC (\"Advisors\"), a registered adviser under the Investment Advisors Act of 1940, as amended, is the sole managing member of GP V. By virtue of such relationships, GP V and Advisors may be deemed to have voting and investment power with respect to the securities held by OPI V noted above and as a result may be deemed to beneficially own such securities for purposes of Rule 13d-3 under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"). Advisors exercised this investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho and Jonathan T. Silverstein, each of whom disclaims beneficial ownership of the Shares held by OPI V. The Reporting Person is an employee of Advisors."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Each of the Reporting Person, GP V and Advisors disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Exchange Act, except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Person, GP V or Advisors is a beneficial owner of such securities for the purposes of Section 16 of the Exchange Act, or for any other purposes."}],"balance_after":847000,"source":{"system":"sec-edgar","filing":"0000947871-20-000193","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1609550/000094787120000193/ownership.xml","form_type":"4"}},{"id":3224548,"issuer":{"id":1186,"kind":"organization","name":"Inspire Medical Systems, Inc.","symbol":"INSP"},"owners":[{"id":111954,"kind":"person","name":"Khuong Chau Quang","position":1,"cik":"0001609405","reported_name":"Khuong Chau Quang","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock, $0.001 par value","published_at":"2020-03-05T23:37:16.000Z","date":"2020-03-04","kind":"sale","acquired":false,"shares":25000,"price":84.55,"value":2113750.0,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"These shares of the Issuer's common stock were sold in a block order at a price of $84.55."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares of the Issuer's common stock are held of record by OPI V. OrbiMed Capital GP V LLC (\"GP V\") is the sole general partner of OPI V, and OrbiMed Advisors LLC (\"Advisors\"), a registered adviser under the Investment Advisors Act of 1940, as amended, is the sole managing member of GP V. By virtue of such relationships, GP V and Advisors may be deemed to have voting and investment power with respect to the securities held by OPI V noted above and as a result may be deemed to beneficially own such securities for purposes of Rule 13d-3 under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"). Advisors exercised this investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho and Jonathan T. Silverstein, each of whom disclaims beneficial ownership of the Shares held by OPI V. The Reporting Person is an employee of Advisors."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Each of the Reporting Person, GP V and Advisors disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Exchange Act, except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Person, GP V or Advisors is a beneficial owner of such securities for the purposes of Section 16 of the Exchange Act, or for any other purposes."}],"balance_after":1247000,"source":{"system":"sec-edgar","filing":"0000947871-20-000193","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1609550/000094787120000193/ownership.xml","form_type":"4"}},{"id":3224547,"issuer":{"id":1186,"kind":"organization","name":"Inspire Medical Systems, Inc.","symbol":"INSP"},"owners":[{"id":111954,"kind":"person","name":"Khuong Chau Quang","position":1,"cik":"0001609405","reported_name":"Khuong Chau Quang","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock, $0.001 par value","published_at":"2020-03-05T23:37:16.000Z","date":"2020-03-03","kind":"sale","acquired":false,"shares":75000,"price":83.21,"value":6240750.0,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"These shares of the Issuer's common stock were sold in a block order at a price of $83.21."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares of the Issuer's common stock are held of record by OPI V. OrbiMed Capital GP V LLC (\"GP V\") is the sole general partner of OPI V, and OrbiMed Advisors LLC (\"Advisors\"), a registered adviser under the Investment Advisors Act of 1940, as amended, is the sole managing member of GP V. By virtue of such relationships, GP V and Advisors may be deemed to have voting and investment power with respect to the securities held by OPI V noted above and as a result may be deemed to beneficially own such securities for purposes of Rule 13d-3 under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"). Advisors exercised this investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho and Jonathan T. Silverstein, each of whom disclaims beneficial ownership of the Shares held by OPI V. The Reporting Person is an employee of Advisors."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Each of the Reporting Person, GP V and Advisors disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Exchange Act, except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Person, GP V or Advisors is a beneficial owner of such securities for the purposes of Section 16 of the Exchange Act, or for any other purposes."}],"balance_after":1272000,"source":{"system":"sec-edgar","filing":"0000947871-20-000193","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1609550/000094787120000193/ownership.xml","form_type":"4"}},{"id":3311623,"issuer":{"id":1186,"kind":"organization","name":"Inspire Medical Systems, Inc.","symbol":"INSP"},"owners":[{"id":111954,"kind":"person","name":"Khuong Chau Quang","position":1,"cik":"0001609405","reported_name":"Khuong Chau Quang","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-01-14T21:05:43.000Z","date":"2020-01-10","kind":"grant","acquired":true,"shares":147,"price":80.63,"value":11852.61,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of common stock received in lieu of cash fees pursuant to the Issuer's Non-Employee Director Compensation Policy."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Pursuant to an agreement with OrbiMed Advisors LLC (\"Advisors\") and OrbiMed Capital GP V LLC (\"GP V\"), the Reporting Person is obligated to transfer these securities, or the economic benefit thereof, to Advisors and GP V, which will in turn ensure that such securities or economic benefits are provided to OrbiMed Private Investments V, LP (\"OPI V\")."}],"balance_after":1473,"source":{"system":"sec-edgar","filing":"0001104659-20-003911","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1609550/000110465920003911/a4.xml","form_type":"4"}},{"id":3356711,"issuer":{"id":1186,"kind":"organization","name":"Inspire Medical Systems, Inc.","symbol":"INSP"},"owners":[{"id":111954,"kind":"person","name":"Khuong Chau Quang","position":1,"cik":"0001609405","reported_name":"Khuong Chau Quang","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock, $0.001 par value","published_at":"2019-11-29T16:53:04.000Z","date":"2019-11-27","kind":"sale","acquired":false,"shares":2306,"price":72.13,"value":166331.78,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction effected pursuant to a Rule 10b5-1 trading plan established by OrbiMed Private Investments V, LP (\"OPI V\") on September 13, 2019."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price recorded in column 4 is a weighted average price. These Shares were sold in multiple transactions at prices ranging from $72.10 to $72.25, inclusive. Upon request, the Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the SEC full information regarding the Shares purchased at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"These securities are held of record by OPI V. OrbiMed Capital GP V LLC (\"GP V\") is the sole general partner of OPI V, and OrbiMed Advisors LLC (\"Advisors\"), a registered adviser under the Investment Advisors Act of 1940, as amended, is the sole managing member of GP V. By virtue of such relationships, GP V and Advisors may be deemed to have voting and investment power with respect to the securities held by OPI V noted above and as a result may be deemed to beneficially own such securities for purposes of Rule 13d-3 under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"). Advisors exercised this investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho and Jonathan T. Silverstein, each of whom disclaims beneficial ownership of the Shares held by OPI V. The Reporting Person is an employee of Advisors."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"Each of the Reporting Person, GP V and Advisors disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Exchange Act, except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Person, GP V or Advisors is a beneficial owner of such securities for the purposes of Section 16 of the Exchange Act, or for any other purposes."}],"balance_after":1347000,"source":{"system":"sec-edgar","filing":"0000947871-19-000875","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1609550/000094787119000875/ownership.xml","form_type":"4"}},{"id":3356710,"issuer":{"id":1186,"kind":"organization","name":"Inspire Medical Systems, Inc.","symbol":"INSP"},"owners":[{"id":111954,"kind":"person","name":"Khuong Chau Quang","position":1,"cik":"0001609405","reported_name":"Khuong Chau Quang","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock, $0.001 par value","published_at":"2019-11-29T16:53:04.000Z","date":"2019-11-27","kind":"sale","acquired":false,"shares":47981,"price":71.67,"value":3438798.27,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction effected pursuant to a Rule 10b5-1 trading plan established by OrbiMed Private Investments V, LP (\"OPI V\") on September 13, 2019."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price recorded in column 4 is a weighted average price. These Shares were sold in multiple transactions at prices ranging from $71.10 to $72.08, inclusive. Upon request, the Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the SEC full information regarding the Shares purchased at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"These securities are held of record by OPI V. OrbiMed Capital GP V LLC (\"GP V\") is the sole general partner of OPI V, and OrbiMed Advisors LLC (\"Advisors\"), a registered adviser under the Investment Advisors Act of 1940, as amended, is the sole managing member of GP V. By virtue of such relationships, GP V and Advisors may be deemed to have voting and investment power with respect to the securities held by OPI V noted above and as a result may be deemed to beneficially own such securities for purposes of Rule 13d-3 under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"). Advisors exercised this investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho and Jonathan T. Silverstein, each of whom disclaims beneficial ownership of the Shares held by OPI V. The Reporting Person is an employee of Advisors."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"Each of the Reporting Person, GP V and Advisors disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Exchange Act, except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Person, GP V or Advisors is a beneficial owner of such securities for the purposes of Section 16 of the Exchange Act, or for any other purposes."}],"balance_after":1349306,"source":{"system":"sec-edgar","filing":"0000947871-19-000875","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1609550/000094787119000875/ownership.xml","form_type":"4"}},{"id":3356709,"issuer":{"id":1186,"kind":"organization","name":"Inspire Medical Systems, Inc.","symbol":"INSP"},"owners":[{"id":111954,"kind":"person","name":"Khuong Chau Quang","position":1,"cik":"0001609405","reported_name":"Khuong Chau Quang","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock, $0.001 par value","published_at":"2019-11-29T16:53:04.000Z","date":"2019-11-27","kind":"sale","acquired":false,"shares":3100,"price":70.6,"value":218860.0,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction effected pursuant to a Rule 10b5-1 trading plan established by OrbiMed Private Investments V, LP (\"OPI V\") on September 13, 2019."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price recorded in column 4 is a weighted average price. These Shares were sold in multiple transactions at prices ranging from $70.08 to $71.03, inclusive. Upon request, the Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the SEC full information regarding the Shares purchased at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"These securities are held of record by OPI V. OrbiMed Capital GP V LLC (\"GP V\") is the sole general partner of OPI V, and OrbiMed Advisors LLC (\"Advisors\"), a registered adviser under the Investment Advisors Act of 1940, as amended, is the sole managing member of GP V. By virtue of such relationships, GP V and Advisors may be deemed to have voting and investment power with respect to the securities held by OPI V noted above and as a result may be deemed to beneficially own such securities for purposes of Rule 13d-3 under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"). Advisors exercised this investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho and Jonathan T. Silverstein, each of whom disclaims beneficial ownership of the Shares held by OPI V. The Reporting Person is an employee of Advisors."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"Each of the Reporting Person, GP V and Advisors disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Exchange Act, except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Person, GP V or Advisors is a beneficial owner of such securities for the purposes of Section 16 of the Exchange Act, or for any other purposes."}],"balance_after":1397287,"source":{"system":"sec-edgar","filing":"0000947871-19-000875","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1609550/000094787119000875/ownership.xml","form_type":"4"}},{"id":3356708,"issuer":{"id":1186,"kind":"organization","name":"Inspire Medical Systems, Inc.","symbol":"INSP"},"owners":[{"id":111954,"kind":"person","name":"Khuong Chau Quang","position":1,"cik":"0001609405","reported_name":"Khuong Chau Quang","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock, $0.001 par value","published_at":"2019-11-29T16:53:04.000Z","date":"2019-11-26","kind":"sale","acquired":false,"shares":50478,"price":70.16,"value":3541536.48,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction effected pursuant to a Rule 10b5-1 trading plan established by OrbiMed Private Investments V, LP (\"OPI V\") on September 13, 2019."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price recorded in column 4 is a weighted average price. These Shares were sold in multiple transactions at prices ranging from $70.00 to $70.76, inclusive. Upon request, the Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the SEC full information regarding the Shares purchased at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"These securities are held of record by OPI V. OrbiMed Capital GP V LLC (\"GP V\") is the sole general partner of OPI V, and OrbiMed Advisors LLC (\"Advisors\"), a registered adviser under the Investment Advisors Act of 1940, as amended, is the sole managing member of GP V. By virtue of such relationships, GP V and Advisors may be deemed to have voting and investment power with respect to the securities held by OPI V noted above and as a result may be deemed to beneficially own such securities for purposes of Rule 13d-3 under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"). Advisors exercised this investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho and Jonathan T. Silverstein, each of whom disclaims beneficial ownership of the Shares held by OPI V. The Reporting Person is an employee of Advisors."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"Each of the Reporting Person, GP V and Advisors disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Exchange Act, except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Person, GP V or Advisors is a beneficial owner of such securities for the purposes of Section 16 of the Exchange Act, or for any other purposes."}],"balance_after":1400387,"source":{"system":"sec-edgar","filing":"0000947871-19-000875","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1609550/000094787119000875/ownership.xml","form_type":"4"}},{"id":3356707,"issuer":{"id":1186,"kind":"organization","name":"Inspire Medical Systems, Inc.","symbol":"INSP"},"owners":[{"id":111954,"kind":"person","name":"Khuong Chau Quang","position":1,"cik":"0001609405","reported_name":"Khuong Chau Quang","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock, $0.001 par value","published_at":"2019-11-29T16:53:04.000Z","date":"2019-11-26","kind":"sale","acquired":false,"shares":20135,"price":69.55,"value":1400389.25,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction effected pursuant to a Rule 10b5-1 trading plan established by OrbiMed Private Investments V, LP (\"OPI V\") on September 13, 2019."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price recorded in column 4 is a weighted average price. These shares of the Issuer's common stock (\"Shares\") were sold in multiple transactions at prices ranging from $69.00 to $69.99, inclusive. Upon request, the Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the Securities and Exchange Commission (the \"SEC\") full information regarding the Shares purchased at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"These securities are held of record by OPI V. OrbiMed Capital GP V LLC (\"GP V\") is the sole general partner of OPI V, and OrbiMed Advisors LLC (\"Advisors\"), a registered adviser under the Investment Advisors Act of 1940, as amended, is the sole managing member of GP V. By virtue of such relationships, GP V and Advisors may be deemed to have voting and investment power with respect to the securities held by OPI V noted above and as a result may be deemed to beneficially own such securities for purposes of Rule 13d-3 under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"). Advisors exercised this investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho and Jonathan T. Silverstein, each of whom disclaims beneficial ownership of the Shares held by OPI V. The Reporting Person is an employee of Advisors."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"Each of the Reporting Person, GP V and Advisors disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Exchange Act, except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Person, GP V or Advisors is a beneficial owner of such securities for the purposes of Section 16 of the Exchange Act, or for any other purposes."}],"balance_after":1450865,"source":{"system":"sec-edgar","filing":"0000947871-19-000875","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1609550/000094787119000875/ownership.xml","form_type":"4"}},{"id":3393685,"issuer":{"id":1186,"kind":"organization","name":"Inspire Medical Systems, Inc.","symbol":"INSP"},"owners":[{"id":111954,"kind":"person","name":"Khuong Chau Quang","position":1,"cik":"0001609405","reported_name":"Khuong Chau Quang","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-10-15T20:19:46.000Z","date":"2019-10-10","kind":"grant","acquired":true,"shares":216,"price":54.84,"value":11845.44,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of common stock received in lieu of cash fees pursuant to the Issuer's Non-Employee Director Compensation Policy."}],"balance_after":1326,"source":{"system":"sec-edgar","filing":"0001104659-19-054158","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1609550/000110465919054158/a4.xml","form_type":"4"}},{"id":3460006,"issuer":{"id":1186,"kind":"organization","name":"Inspire Medical Systems, Inc.","symbol":"INSP"},"owners":[{"id":111954,"kind":"person","name":"Khuong Chau Quang","position":1,"cik":"0001609405","reported_name":"Khuong Chau Quang","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-07-17T20:52:49.000Z","date":"2019-07-15","kind":"grant","acquired":true,"shares":172,"price":68.88,"value":11847.36,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of common stock received in lieu of cash fees pursuant to the Issuer's Non-Employee Director Compensation Policy."}],"balance_after":1110,"source":{"system":"sec-edgar","filing":"0001104659-19-040771","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1609550/000110465919040771/a4.xml","form_type":"4"}},{"id":3484026,"issuer":{"id":6074,"kind":"organization","name":"Whitehawk Therapeutics, Inc.","symbol":"WHWK"},"owners":[{"id":111954,"kind":"person","name":"Khuong Chau Quang","position":1,"cik":"0001609405","reported_name":"Khuong Chau Quang","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2019-06-19T21:26:50.000Z","date":"2019-06-18","kind":"grant","acquired":true,"shares":21400,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Options shall vest annually on the earlier of the one year anniversary of the Grant Date or the Company's next annual meeting, subject to director's continued service on the Board at such time."}],"balance_after":21400,"derivative":{"exercise_price":0.96,"expiration_date":"2029-06-18","underlying":"Common Stock","underlying_shares":21400},"source":{"system":"sec-edgar","filing":"0000899243-19-017441","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1422142/000089924319017441/doc4.xml","form_type":"4"}},{"id":3487274,"issuer":{"id":7461,"kind":"organization","name":"NextCure, Inc."},"owners":[{"id":111954,"kind":"person","name":"Khuong Chau Quang","position":1,"cik":"0001609405","reported_name":"Khuong Chau Quang","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2019-06-17T20:22:36.000Z","date":"2019-06-13","kind":"grant","acquired":true,"shares":22000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests in three equal annual installments beginning on June 13, 2020."}],"balance_after":22000,"derivative":{"exercise_price":15.57,"expiration_date":"2029-06-12","underlying":"Common Stock","underlying_shares":22000},"source":{"system":"sec-edgar","filing":"0001123292-19-000891","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1609405/000112329219000891/edgar.xml","form_type":"4"}},{"id":3496764,"issuer":{"id":7801,"kind":"organization","name":"SYNLOGIC, INC."},"owners":[{"id":111954,"kind":"person","name":"Khuong Chau Quang","position":1,"cik":"0001609405","reported_name":"Khuong Chau Quang","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2019-06-07T20:15:19.000Z","date":"2019-06-05","kind":"grant","acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests and becomes exercisable in full on the earlier of (A) the first anniversary of the date of grant or (B) immediately prior to the next annual meeting of the Corporation's stockholders after the date of grant, subject in each case to each non-employee director's continued service as a director of the Corporation."}],"balance_after":10000,"derivative":{"exercise_price":7.3,"expiration_date":"2029-06-05","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0000899243-19-015993","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1527599/000089924319015993/doc4.xml","form_type":"4"}},{"id":3529116,"issuer":{"id":7461,"kind":"organization","name":"NextCure, Inc."},"owners":[{"id":111954,"kind":"person","name":"Khuong Chau Quang","position":1,"cik":"0001609405","reported_name":"Khuong Chau Quang","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series B-1 Preferred Stock","published_at":"2019-05-13T19:32:49.000Z","date":"2019-05-13","kind":"exercise","acquired":false,"shares":3554466,"ownership":{"direct":false,"nature":"By OrbiMed Private Investments VI, LP"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The reported securities automatically converted into shares of Common Stock on a 1-for-8.0338 basis upon the closing of the Issuer's initial public offering and had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The reported securities automatically converted into shares of Common Stock on a 1-for-8.0338 basis upon the closing of the Issuer's initial public offering and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The reported securities automatically converted into shares of Common Stock on a 1-for-8.0338 basis upon the closing of the Issuer's initial public offering and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The reported securities automatically converted into shares of Common Stock on a 1-for-8.0338 basis upon the closing of the Issuer's initial public offering and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"OrbiMed Capital GP VI LLC (\"GP VI\") is the sole general partner of OrbiMed Private Investments VI, LP (\"OPI VI\"). OrbiMed Advisors LLC (\"OrbiMed Advisors\") is the managing member of GP VI. By virtue of such relationships, GP VI and OrbiMed Advisors may be deemed to have voting and investment power with respect to the shares held by OPI VI and as a result may be deemed to have beneficial ownership of such shares. The Reporting Person is an employee of OrbiMed Advisors. OrbiMed Advisors exercises investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho and Jonathan T. Silverstein. Each of GP VI, OrbiMed Advisors and the Reporting Person disclaims beneficial ownership of the shares held by OPI VI, except to the extent of its or his pecuniary interest therein, if any."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":442438},"source":{"system":"sec-edgar","filing":"0001123292-19-000751","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1609405/000112329219000751/edgar.xml","form_type":"4"}},{"id":3529115,"issuer":{"id":7461,"kind":"organization","name":"NextCure, Inc."},"owners":[{"id":111954,"kind":"person","name":"Khuong Chau Quang","position":1,"cik":"0001609405","reported_name":"Khuong Chau Quang","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series A-3 Preferred Stock","published_at":"2019-05-13T19:32:49.000Z","date":"2019-05-13","kind":"exercise","acquired":false,"shares":5861455,"ownership":{"direct":false,"nature":"By OrbiMed Private Investments VI, LP"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The reported securities automatically converted into shares of Common Stock on a 1-for-8.0338 basis upon the closing of the Issuer's initial public offering and had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The reported securities automatically converted into shares of Common Stock on a 1-for-8.0338 basis upon the closing of the Issuer's initial public offering and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The reported securities automatically converted into shares of Common Stock on a 1-for-8.0338 basis upon the closing of the Issuer's initial public offering and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The reported securities automatically converted into shares of Common Stock on a 1-for-8.0338 basis upon the closing of the Issuer's initial public offering and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"OrbiMed Capital GP VI LLC (\"GP VI\") is the sole general partner of OrbiMed Private Investments VI, LP (\"OPI VI\"). OrbiMed Advisors LLC (\"OrbiMed Advisors\") is the managing member of GP VI. By virtue of such relationships, GP VI and OrbiMed Advisors may be deemed to have voting and investment power with respect to the shares held by OPI VI and as a result may be deemed to have beneficial ownership of such shares. The Reporting Person is an employee of OrbiMed Advisors. OrbiMed Advisors exercises investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho and Jonathan T. Silverstein. Each of GP VI, OrbiMed Advisors and the Reporting Person disclaims beneficial ownership of the shares held by OPI VI, except to the extent of its or his pecuniary interest therein, if any."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":729599},"source":{"system":"sec-edgar","filing":"0001123292-19-000751","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1609405/000112329219000751/edgar.xml","form_type":"4"}},{"id":3529114,"issuer":{"id":7461,"kind":"organization","name":"NextCure, Inc."},"owners":[{"id":111954,"kind":"person","name":"Khuong Chau Quang","position":1,"cik":"0001609405","reported_name":"Khuong Chau Quang","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series A-2 Preferred Stock","published_at":"2019-05-13T19:32:49.000Z","date":"2019-05-13","kind":"exercise","acquired":false,"shares":5970000,"ownership":{"direct":false,"nature":"By OrbiMed Private Investments VI, LP"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The reported securities automatically converted into shares of Common Stock on a 1-for-8.0338 basis upon the closing of the Issuer's initial public offering and had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The reported securities automatically converted into shares of Common Stock on a 1-for-8.0338 basis upon the closing of the Issuer's initial public offering and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The reported securities automatically converted into shares of Common Stock on a 1-for-8.0338 basis upon the closing of the Issuer's initial public offering and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The reported securities automatically converted into shares of Common Stock on a 1-for-8.0338 basis upon the closing of the Issuer's initial public offering and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"OrbiMed Capital GP VI LLC (\"GP VI\") is the sole general partner of OrbiMed Private Investments VI, LP (\"OPI VI\"). OrbiMed Advisors LLC (\"OrbiMed Advisors\") is the managing member of GP VI. By virtue of such relationships, GP VI and OrbiMed Advisors may be deemed to have voting and investment power with respect to the shares held by OPI VI and as a result may be deemed to have beneficial ownership of such shares. The Reporting Person is an employee of OrbiMed Advisors. OrbiMed Advisors exercises investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho and Jonathan T. Silverstein. Each of GP VI, OrbiMed Advisors and the Reporting Person disclaims beneficial ownership of the shares held by OPI VI, except to the extent of its or his pecuniary interest therein, if any."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":743110},"source":{"system":"sec-edgar","filing":"0001123292-19-000751","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1609405/000112329219000751/edgar.xml","form_type":"4"}},{"id":3529113,"issuer":{"id":7461,"kind":"organization","name":"NextCure, Inc."},"owners":[{"id":111954,"kind":"person","name":"Khuong Chau Quang","position":1,"cik":"0001609405","reported_name":"Khuong Chau Quang","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series A-1 Preferred Stock","published_at":"2019-05-13T19:32:49.000Z","date":"2019-05-13","kind":"exercise","acquired":false,"shares":3582000,"ownership":{"direct":false,"nature":"By OrbiMed Private Investments VI, LP"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The reported securities automatically converted into shares of Common Stock on a 1-for-8.0338 basis upon the closing of the Issuer's initial public offering and had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The reported securities automatically converted into shares of Common Stock on a 1-for-8.0338 basis upon the closing of the Issuer's initial public offering and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The reported securities automatically converted into shares of Common Stock on a 1-for-8.0338 basis upon the closing of the Issuer's initial public offering and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The reported securities automatically converted into shares of Common Stock on a 1-for-8.0338 basis upon the closing of the Issuer's initial public offering and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"OrbiMed Capital GP VI LLC (\"GP VI\") is the sole general partner of OrbiMed Private Investments VI, LP (\"OPI VI\"). OrbiMed Advisors LLC (\"OrbiMed Advisors\") is the managing member of GP VI. By virtue of such relationships, GP VI and OrbiMed Advisors may be deemed to have voting and investment power with respect to the shares held by OPI VI and as a result may be deemed to have beneficial ownership of such shares. The Reporting Person is an employee of OrbiMed Advisors. OrbiMed Advisors exercises investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho and Jonathan T. Silverstein. Each of GP VI, OrbiMed Advisors and the Reporting Person disclaims beneficial ownership of the shares held by OPI VI, except to the extent of its or his pecuniary interest therein, if any."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":445866},"source":{"system":"sec-edgar","filing":"0001123292-19-000751","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1609405/000112329219000751/edgar.xml","form_type":"4"}},{"id":3529112,"issuer":{"id":7461,"kind":"organization","name":"NextCure, Inc."},"owners":[{"id":111954,"kind":"person","name":"Khuong Chau Quang","position":1,"cik":"0001609405","reported_name":"Khuong Chau Quang","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-05-13T19:32:49.000Z","date":"2019-05-13","kind":"purchase","acquired":true,"shares":350000,"price":15,"value":5250000.0,"ownership":{"direct":false,"nature":"By OrbiMed Private Investments VI, LP"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"OrbiMed Capital GP VI LLC (\"GP VI\") is the sole general partner of OrbiMed Private Investments VI, LP (\"OPI VI\"). OrbiMed Advisors LLC (\"OrbiMed Advisors\") is the managing member of GP VI. By virtue of such relationships, GP VI and OrbiMed Advisors may be deemed to have voting and investment power with respect to the shares held by OPI VI and as a result may be deemed to have beneficial ownership of such shares. The Reporting Person is an employee of OrbiMed Advisors. OrbiMed Advisors exercises investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho and Jonathan T. Silverstein. Each of GP VI, OrbiMed Advisors and the Reporting Person disclaims beneficial ownership of the shares held by OPI VI, except to the extent of its or his pecuniary interest therein, if any."}],"balance_after":2711013,"source":{"system":"sec-edgar","filing":"0001123292-19-000751","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1609405/000112329219000751/edgar.xml","form_type":"4"}},{"id":3529111,"issuer":{"id":7461,"kind":"organization","name":"NextCure, Inc."},"owners":[{"id":111954,"kind":"person","name":"Khuong Chau Quang","position":1,"cik":"0001609405","reported_name":"Khuong Chau Quang","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-05-13T19:32:49.000Z","date":"2019-05-13","kind":"exercise","acquired":true,"shares":442438,"ownership":{"direct":false,"nature":"By OrbiMed Private Investments VI, LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The reported securities automatically converted into shares of Common Stock on a 1-for-8.0338 basis upon the closing of the Issuer's initial public offering and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"OrbiMed Capital GP VI LLC (\"GP VI\") is the sole general partner of OrbiMed Private Investments VI, LP (\"OPI VI\"). OrbiMed Advisors LLC (\"OrbiMed Advisors\") is the managing member of GP VI. By virtue of such relationships, GP VI and OrbiMed Advisors may be deemed to have voting and investment power with respect to the shares held by OPI VI and as a result may be deemed to have beneficial ownership of such shares. The Reporting Person is an employee of OrbiMed Advisors. OrbiMed Advisors exercises investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho and Jonathan T. Silverstein. Each of GP VI, OrbiMed Advisors and the Reporting Person disclaims beneficial ownership of the shares held by OPI VI, except to the extent of its or his pecuniary interest therein, if any."}],"balance_after":2361013,"source":{"system":"sec-edgar","filing":"0001123292-19-000751","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1609405/000112329219000751/edgar.xml","form_type":"4"}},{"id":3529110,"issuer":{"id":7461,"kind":"organization","name":"NextCure, Inc."},"owners":[{"id":111954,"kind":"person","name":"Khuong Chau Quang","position":1,"cik":"0001609405","reported_name":"Khuong Chau Quang","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-05-13T19:32:49.000Z","date":"2019-05-13","kind":"exercise","acquired":true,"shares":729599,"ownership":{"direct":false,"nature":"By OrbiMed Private Investments VI, LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The reported securities automatically converted into shares of Common Stock on a 1-for-8.0338 basis upon the closing of the Issuer's initial public offering and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"OrbiMed Capital GP VI LLC (\"GP VI\") is the sole general partner of OrbiMed Private Investments VI, LP (\"OPI VI\"). OrbiMed Advisors LLC (\"OrbiMed Advisors\") is the managing member of GP VI. By virtue of such relationships, GP VI and OrbiMed Advisors may be deemed to have voting and investment power with respect to the shares held by OPI VI and as a result may be deemed to have beneficial ownership of such shares. The Reporting Person is an employee of OrbiMed Advisors. OrbiMed Advisors exercises investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho and Jonathan T. Silverstein. Each of GP VI, OrbiMed Advisors and the Reporting Person disclaims beneficial ownership of the shares held by OPI VI, except to the extent of its or his pecuniary interest therein, if any."}],"balance_after":1918575,"source":{"system":"sec-edgar","filing":"0001123292-19-000751","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1609405/000112329219000751/edgar.xml","form_type":"4"}},{"id":3529109,"issuer":{"id":7461,"kind":"organization","name":"NextCure, Inc."},"owners":[{"id":111954,"kind":"person","name":"Khuong Chau Quang","position":1,"cik":"0001609405","reported_name":"Khuong Chau Quang","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-05-13T19:32:49.000Z","date":"2019-05-13","kind":"exercise","acquired":true,"shares":743110,"ownership":{"direct":false,"nature":"By OrbiMed Private Investments VI, LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The reported securities automatically converted into shares of Common Stock on a 1-for-8.0338 basis upon the closing of the Issuer's initial public offering and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"OrbiMed Capital GP VI LLC (\"GP VI\") is the sole general partner of OrbiMed Private Investments VI, LP (\"OPI VI\"). OrbiMed Advisors LLC (\"OrbiMed Advisors\") is the managing member of GP VI. By virtue of such relationships, GP VI and OrbiMed Advisors may be deemed to have voting and investment power with respect to the shares held by OPI VI and as a result may be deemed to have beneficial ownership of such shares. The Reporting Person is an employee of OrbiMed Advisors. OrbiMed Advisors exercises investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho and Jonathan T. Silverstein. Each of GP VI, OrbiMed Advisors and the Reporting Person disclaims beneficial ownership of the shares held by OPI VI, except to the extent of its or his pecuniary interest therein, if any."}],"balance_after":1188976,"source":{"system":"sec-edgar","filing":"0001123292-19-000751","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1609405/000112329219000751/edgar.xml","form_type":"4"}},{"id":3529108,"issuer":{"id":7461,"kind":"organization","name":"NextCure, Inc."},"owners":[{"id":111954,"kind":"person","name":"Khuong Chau Quang","position":1,"cik":"0001609405","reported_name":"Khuong Chau Quang","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-05-13T19:32:49.000Z","date":"2019-05-13","kind":"exercise","acquired":true,"shares":445866,"ownership":{"direct":false,"nature":"By OrbiMed Private Investments VI, LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The reported securities automatically converted into shares of Common Stock on a 1-for-8.0338 basis upon the closing of the Issuer's initial public offering and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"OrbiMed Capital GP VI LLC (\"GP VI\") is the sole general partner of OrbiMed Private Investments VI, LP (\"OPI VI\"). OrbiMed Advisors LLC (\"OrbiMed Advisors\") is the managing member of GP VI. By virtue of such relationships, GP VI and OrbiMed Advisors may be deemed to have voting and investment power with respect to the shares held by OPI VI and as a result may be deemed to have beneficial ownership of such shares. The Reporting Person is an employee of OrbiMed Advisors. OrbiMed Advisors exercises investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho and Jonathan T. Silverstein. Each of GP VI, OrbiMed Advisors and the Reporting Person disclaims beneficial ownership of the shares held by OPI VI, except to the extent of its or his pecuniary interest therein, if any."}],"balance_after":445866,"source":{"system":"sec-edgar","filing":"0001123292-19-000751","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1609405/000112329219000751/edgar.xml","form_type":"4"}},{"id":3538073,"issuer":{"id":1186,"kind":"organization","name":"Inspire Medical Systems, Inc.","symbol":"INSP"},"owners":[{"id":111954,"kind":"person","name":"Khuong Chau Quang","position":1,"cik":"0001609405","reported_name":"Khuong Chau Quang","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2019-05-06T22:13:19.000Z","date":"2019-05-02","kind":"grant","acquired":true,"shares":4569,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests and becomes exercisable on May 2, 2020, subject to the Reporting Person's continuous service to the Issuer through such date."}],"balance_after":4569,"derivative":{"exercise_price":49.96,"expiration_date":"2029-05-02","underlying":"Common Stock","underlying_shares":4569},"source":{"system":"sec-edgar","filing":"0001104659-19-027225","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1609550/000110465919027225/a4.xml","form_type":"4"}},{"id":3556637,"issuer":{"id":1186,"kind":"organization","name":"Inspire Medical Systems, Inc.","symbol":"INSP"},"owners":[{"id":111954,"kind":"person","name":"Khuong Chau Quang","position":1,"cik":"0001609405","reported_name":"Khuong Chau Quang","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-04-12T20:29:37.000Z","date":"2019-04-10","kind":"grant","acquired":true,"shares":213,"price":55.63,"value":11849.19,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of common stock received in lieu of cash fees pursuant to the Issuer's Non-Employee Director Compensation Policy."}],"balance_after":938,"source":{"system":"sec-edgar","filing":"0001104659-19-021132","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1609550/000110465919021132/a4.xml","form_type":"4"}},{"id":3601873,"issuer":{"id":1186,"kind":"organization","name":"Inspire Medical Systems, Inc.","symbol":"INSP"},"owners":[{"id":111954,"kind":"person","name":"Khuong Chau Quang","position":1,"cik":"0001609405","reported_name":"Khuong Chau Quang","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock, $0.001 par value","published_at":"2019-03-12T01:25:34.000Z","date":"2019-03-08","kind":"sale","acquired":false,"shares":290231,"price":57.75,"value":16760840.25,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"These Shares were sold in a block order at a price of $57.75."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These securities are held of record by OrbiMed Private Investments V, LP (\"OPI V\"). OrbiMed Capital GP V LLC (\"GP V\") is the sole general partner of OPI V, and OrbiMed Advisors LLC (\"Advisors\"), a registered adviser under the Investment Advisors Act of 1940, as amended, is the sole managing member of GP V. By virtue of such relationships, GP V and Advisors may be deemed to have voting and investment power with respect to the securities held by OPI V noted above and as a result may be deemed to beneficially own such securities for purposes of Rule 13d-3 under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"). Advisors exercised this investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho and Jonathan T. Silverstein, each of whom disclaims beneficial ownership of the Shares held by OPI V. The Reporting Person is an employee of Advisors."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Each of the Reporting Person, GP V and Advisors disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Exchange Act, except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Persons is a beneficial owner of such securities for the purposes of Section 16 of the Exchange Act, or for any other purposes."}],"balance_after":1471000,"source":{"system":"sec-edgar","filing":"0000947871-19-000200","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1609550/000094787119000200/ownership.xml","form_type":"4"}},{"id":3601872,"issuer":{"id":1186,"kind":"organization","name":"Inspire Medical Systems, Inc.","symbol":"INSP"},"owners":[{"id":111954,"kind":"person","name":"Khuong Chau Quang","position":1,"cik":"0001609405","reported_name":"Khuong Chau Quang","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock, $0.001 par value","published_at":"2019-03-12T01:25:34.000Z","date":"2019-03-07","kind":"sale","acquired":false,"shares":68218,"price":55.01,"value":3752672.18,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares of the Issuer's common stock (\"Shares\") were sold in multiple transactions at prices ranging from $54.89 to $55.26 inclusive. Upon request, the Reporting Persons undertakes to provide the Issuer, any security holder of the Issuer, or the Securities and Exchange Commission (the \"SEC\") full information regarding the Shares purchased at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These securities are held of record by OrbiMed Private Investments V, LP (\"OPI V\"). OrbiMed Capital GP V LLC (\"GP V\") is the sole general partner of OPI V, and OrbiMed Advisors LLC (\"Advisors\"), a registered adviser under the Investment Advisors Act of 1940, as amended, is the sole managing member of GP V. By virtue of such relationships, GP V and Advisors may be deemed to have voting and investment power with respect to the securities held by OPI V noted above and as a result may be deemed to beneficially own such securities for purposes of Rule 13d-3 under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"). Advisors exercised this investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho and Jonathan T. Silverstein, each of whom disclaims beneficial ownership of the Shares held by OPI V. The Reporting Person is an employee of Advisors."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Each of the Reporting Person, GP V and Advisors disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Exchange Act, except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Persons is a beneficial owner of such securities for the purposes of Section 16 of the Exchange Act, or for any other purposes."}],"balance_after":1761231,"source":{"system":"sec-edgar","filing":"0000947871-19-000200","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1609550/000094787119000200/ownership.xml","form_type":"4"}},{"id":3696449,"issuer":{"id":1186,"kind":"organization","name":"Inspire Medical Systems, Inc.","symbol":"INSP"},"owners":[{"id":111954,"kind":"person","name":"Khuong Chau Quang","position":1,"cik":"0001609405","reported_name":"Khuong Chau Quang","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-01-14T21:30:45.000Z","date":"2019-01-10","kind":"grant","acquired":true,"shares":254,"price":46.58,"value":11831.32,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of vested, restricted common stock received in lieu of cash fees pursuant to the Issuer's Non-Employee Director Compensation Policy, which shares are subject to the Reporting Person's lock-up agreement entered into in connection with the Registrant's public offering of common stock consummated on December 11, 2018."}],"balance_after":725,"source":{"system":"sec-edgar","filing":"0001104659-19-001829","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1609550/000110465919001829/a4.xml","form_type":"4"}},{"id":3732168,"issuer":{"id":1186,"kind":"organization","name":"Inspire Medical Systems, Inc.","symbol":"INSP"},"owners":[{"id":111954,"kind":"person","name":"Khuong Chau Quang","position":1,"cik":"0001609405","reported_name":"Khuong Chau Quang","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-12-13T21:38:54.000Z","date":"2018-12-11","kind":"sale","acquired":false,"shares":614772,"price":37.6,"value":23115427.2,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"These shares of the Issuer's common stock were sold in a block order at a price of $37.60."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held of record by OrbiMed Private Investments V, LP (\"OPI V\"). OrbiMed Capital GP V LLC (\"GP V\") is the sole general partner of OPI V, and OrbiMed Advisors LLC (\"Advisors\"), a registered adviser under the Investment Advisors Act of 1940, as amended, is the sole managing member of GP V. By virtue of such relationships, GP V and Advisors may be deemed to have voting and investment power with respect to the securities held by OPI V noted above and as a result may be deemed to beneficially own such securities for purposes of Rule 13d-3 under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"). Advisors exercised this investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho and Jonathan T. Silverstein, each of whom disclaims beneficial ownership of the securities held by OPI V. The Reporting Person is an employee of Advisors."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Each of the Reporting Person, GP V and Advisors disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) of the Exchange Act, except to the extent of its or his pecuniary interest therein, if any. This report shall not be deemed an admission that any such entity or person, including the Reporting Person, is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":1829449,"source":{"system":"sec-edgar","filing":"0000947871-18-000972","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1609550/000094787118000972/ownership.xml","form_type":"4"}},{"id":3791946,"issuer":{"id":1186,"kind":"organization","name":"Inspire Medical Systems, Inc.","symbol":"INSP"},"owners":[{"id":111954,"kind":"person","name":"Khuong Chau Quang","position":1,"cik":"0001609405","reported_name":"Khuong Chau Quang","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-10-12T15:47:31.000Z","date":"2018-10-10","kind":"grant","acquired":true,"shares":292,"price":40.6,"value":11855.2,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of vested, restricted common stock received in lieu of cash fees pursuant to the Issuer's Non-Employee Director Compensation Policy, which shares are subject to the Reporting Person's lock-up agreement entered into in connection with the Registrant's initial public offering."}],"balance_after":471,"source":{"system":"sec-edgar","filing":"0001104659-18-061738","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1609550/000110465918061738/a4.xml","form_type":"4"}},{"id":3867292,"issuer":{"id":1186,"kind":"organization","name":"Inspire Medical Systems, Inc.","symbol":"INSP"},"owners":[{"id":111954,"kind":"person","name":"Khuong Chau Quang","position":1,"cik":"0001609405","reported_name":"Khuong Chau Quang","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-07-16T20:19:07.000Z","date":"2018-07-12","kind":"grant","acquired":true,"shares":179,"price":43,"value":7697.0,"ownership":{"direct":true},"balance_after":179,"source":{"system":"sec-edgar","filing":"0001104659-18-045276","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1609550/000110465918045276/a4.xml","form_type":"4"}},{"id":3878629,"issuer":{"id":6074,"kind":"organization","name":"Whitehawk Therapeutics, Inc.","symbol":"WHWK"},"owners":[{"id":111954,"kind":"person","name":"Khuong Chau Quang","position":1,"cik":"0001609405","reported_name":"Khuong Chau Quang","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2018-07-02T20:51:38.000Z","date":"2018-06-28","kind":"purchase","acquired":true,"shares":777500,"price":3.85,"value":2993375.0,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"These shares of the Issuer's common stock (\"Shares\") were purchased in a block order at a price of $3.85."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These Shares are held of record by OrbiMed Private Investments V, LP (\"OPI V\"). OrbiMed Capital GP V LLC (\"GP V\") is the general partner of OPI V, and OrbiMed Advisors LLC (\"Advisors\"), a registered adviser under the Investment Advisors Act of 1940, as amended, is the managing member of GP V. By virtue of such relationships, GP V and Advisors may be deemed to have voting and investment power over the securities held by OPI V and as a result may be deemed to beneficially own such securities for purposes of Rule 13d-3 under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"). Advisors exercised this investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho and Jonathan T. Silverstein, each of whom disclaims beneficial ownership of the Shares held by OPI V."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Each of the Reporting Person, GP V and Advisors disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) of the Exchange Act, except to the extent of its or his pecuniary interest therein, if any. This report shall not be deemed an admission that any such entity or person, including the Reporting Person, is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":5193946,"source":{"system":"sec-edgar","filing":"0000947871-18-000541","document":"ss98059_4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1422142/000094787118000541/ss98059_4.xml","form_type":"4"}},{"id":3884942,"issuer":{"id":6074,"kind":"organization","name":"Whitehawk Therapeutics, Inc.","symbol":"WHWK"},"owners":[{"id":111954,"kind":"person","name":"Khuong Chau Quang","position":1,"cik":"0001609405","reported_name":"Khuong Chau Quang","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2018-06-22T22:08:23.000Z","date":"2018-06-20","kind":"grant","acquired":true,"shares":21400,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Options shall vest annually on the earlier of the one year anniversary of the Grant Date or the Company's next annual meeting, subject to director's continued service on the Board at such time."}],"balance_after":21400,"derivative":{"exercise_price":4,"expiration_date":"2028-06-20","underlying":"Common Stock","underlying_shares":21400},"source":{"system":"sec-edgar","filing":"0000899243-18-017752","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1422142/000089924318017752/doc4.xml","form_type":"4"}},{"id":3893489,"issuer":{"id":7801,"kind":"organization","name":"SYNLOGIC, INC."},"owners":[{"id":111954,"kind":"person","name":"Khuong Chau Quang","position":1,"cik":"0001609405","reported_name":"Khuong Chau Quang","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2018-06-14T20:05:32.000Z","date":"2018-06-13","kind":"grant","acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests and becomes exercisable in full on the earlier of (A) the first anniversary of the date of grant or (B) immediately prior to the next annual meeting of the Corporation's stockholders after the date of grant, subject in each case to the reporting person's continued service as a director of the Corporation."}],"balance_after":10000,"derivative":{"exercise_price":9.36,"expiration_date":"2028-06-13","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0000899243-18-016590","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1527599/000089924318016590/doc4.xml","form_type":"4"}},{"id":3941053,"issuer":{"id":1186,"kind":"organization","name":"Inspire Medical Systems, Inc.","symbol":"INSP"},"owners":[{"id":111954,"kind":"person","name":"Khuong Chau Quang","position":1,"cik":"0001609405","reported_name":"Khuong Chau Quang","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Employee Stock Option (right to buy)","published_at":"2018-05-10T01:22:26.000Z","date":"2018-05-02","kind":"grant","acquired":true,"shares":17296,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The option vests and becomes exercisable on May 2, 2019, subject to the Reporting Person's continuous service to the Issuer through such date.  The option was erroneously included on the Reporting Person's Form 3 filed on May 2, 2018."}],"balance_after":17296,"derivative":{"exercise_price":16,"expiration_date":"2028-05-02","underlying":"Common Stock","underlying_shares":17296},"source":{"system":"sec-edgar","filing":"0001104659-18-031869","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1609550/000110465918031869/a4.xml","form_type":"4"}},{"id":3941052,"issuer":{"id":1186,"kind":"organization","name":"Inspire Medical Systems, Inc.","symbol":"INSP"},"owners":[{"id":111954,"kind":"person","name":"Khuong Chau Quang","position":1,"cik":"0001609405","reported_name":"Khuong Chau Quang","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series F Convertible Preferred Stock","published_at":"2018-05-10T01:22:26.000Z","date":"2018-05-07","kind":"exercise","acquired":false,"shares":3649635,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Shares of Series F Convertible Preferred Stock automatically converted into shares of the Issuer's Common Stock at a 1-for-0.1504 conversion rate immediately prior to the closing of the Issuer's IPO for no additional consideration (subject to the payment of cash in lieu of any fractional shares in accordance with the Issuer's Certificate of Incorporation).  These shares had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Shares of Series F Convertible Preferred Stock automatically converted into shares of the Issuer's Common Stock at a 1-for-0.1504 conversion rate immediately prior to the closing of the Issuer's IPO for no additional consideration (subject to the payment of cash in lieu of any fractional shares in accordance with the Issuer's Certificate of Incorporation).  These shares had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Shares of Series F Convertible Preferred Stock automatically converted into shares of the Issuer's Common Stock at a 1-for-0.1504 conversion rate immediately prior to the closing of the Issuer's IPO for no additional consideration (subject to the payment of cash in lieu of any fractional shares in accordance with the Issuer's Certificate of Incorporation).  These shares had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These securities are held of record by OrbiMed Private Investments V, LP (\"OPI V\").  OrbiMed Capital GP V LLC (\"GP V\") is the sole general partner of OPI V, and OrbiMed Advisors LLC (\"Advisors\"), a registered adviser under the Investment Advisors Act of 1940, as amended, is the sole managing member of GP V.  By virtue of such relationships, GP V and Advisors may be deemed to have voting and investment power with respect to the securities held by OPI V noted above and as a result may be deemed to beneficially own such securities for purposes of Rule 13d-3 under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\").  Advisors exercised this investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho and Jonathan T. Silverstein, each of whom disclaims beneficial ownership of the Shares held by OPI V. The Reporting Person is an employee of Advisors."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Each of the Reporting Person, GP V and Advisors disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) of the Exchange Act, except to the extent of its or his pecuniary interest therein, if any.  This report shall not be deemed an admission that any such entity or person, including the Reporting Person, is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":548817},"source":{"system":"sec-edgar","filing":"0001104659-18-031869","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1609550/000110465918031869/a4.xml","form_type":"4"}},{"id":3941051,"issuer":{"id":1186,"kind":"organization","name":"Inspire Medical Systems, Inc.","symbol":"INSP"},"owners":[{"id":111954,"kind":"person","name":"Khuong Chau Quang","position":1,"cik":"0001609405","reported_name":"Khuong Chau Quang","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series E Convertible Preferred Stock","published_at":"2018-05-10T01:22:26.000Z","date":"2018-05-07","kind":"exercise","acquired":false,"shares":9160305,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Shares of Series E Convertible Preferred Stock automatically converted into shares of the Issuer's Common Stock at a 1-for-0.1728 conversion rate immediately prior to the closing of the Issuer's initial public offering (\"IPO\") for no additional consideration (subject to the payment of cash in lieu of any fractional shares in accordance with the Issuer's Sixth Amended and Restated Certificate of Incorporation (as amended, the \"Certificate of Incorporation\").  These shares had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Shares of Series E Convertible Preferred Stock automatically converted into shares of the Issuer's Common Stock at a 1-for-0.1728 conversion rate immediately prior to the closing of the Issuer's initial public offering (\"IPO\") for no additional consideration (subject to the payment of cash in lieu of any fractional shares in accordance with the Issuer's Sixth Amended and Restated Certificate of Incorporation (as amended, the \"Certificate of Incorporation\").  These shares had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Shares of Series E Convertible Preferred Stock automatically converted into shares of the Issuer's Common Stock at a 1-for-0.1728 conversion rate immediately prior to the closing of the Issuer's initial public offering (\"IPO\") for no additional consideration (subject to the payment of cash in lieu of any fractional shares in accordance with the Issuer's Sixth Amended and Restated Certificate of Incorporation (as amended, the \"Certificate of Incorporation\").  These shares had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These securities are held of record by OrbiMed Private Investments V, LP (\"OPI V\").  OrbiMed Capital GP V LLC (\"GP V\") is the sole general partner of OPI V, and OrbiMed Advisors LLC (\"Advisors\"), a registered adviser under the Investment Advisors Act of 1940, as amended, is the sole managing member of GP V.  By virtue of such relationships, GP V and Advisors may be deemed to have voting and investment power with respect to the securities held by OPI V noted above and as a result may be deemed to beneficially own such securities for purposes of Rule 13d-3 under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\").  Advisors exercised this investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho and Jonathan T. Silverstein, each of whom disclaims beneficial ownership of the Shares held by OPI V. The Reporting Person is an employee of Advisors."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Each of the Reporting Person, GP V and Advisors disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) of the Exchange Act, except to the extent of its or his pecuniary interest therein, if any.  This report shall not be deemed an admission that any such entity or person, including the Reporting Person, is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1582904},"source":{"system":"sec-edgar","filing":"0001104659-18-031869","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1609550/000110465918031869/a4.xml","form_type":"4"}},{"id":3941050,"issuer":{"id":1186,"kind":"organization","name":"Inspire Medical Systems, Inc.","symbol":"INSP"},"owners":[{"id":111954,"kind":"person","name":"Khuong Chau Quang","position":1,"cik":"0001609405","reported_name":"Khuong Chau Quang","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2018-05-10T01:22:26.000Z","date":"2018-05-07","kind":"purchase","acquired":true,"shares":312500,"price":16,"value":5000000.0,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These securities are held of record by OrbiMed Private Investments V, LP (\"OPI V\").  OrbiMed Capital GP V LLC (\"GP V\") is the sole general partner of OPI V, and OrbiMed Advisors LLC (\"Advisors\"), a registered adviser under the Investment Advisors Act of 1940, as amended, is the sole managing member of GP V.  By virtue of such relationships, GP V and Advisors may be deemed to have voting and investment power with respect to the securities held by OPI V noted above and as a result may be deemed to beneficially own such securities for purposes of Rule 13d-3 under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\").  Advisors exercised this investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho and Jonathan T. Silverstein, each of whom disclaims beneficial ownership of the Shares held by OPI V. The Reporting Person is an employee of Advisors."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Each of the Reporting Person, GP V and Advisors disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) of the Exchange Act, except to the extent of its or his pecuniary interest therein, if any.  This report shall not be deemed an admission that any such entity or person, including the Reporting Person, is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":2444221,"source":{"system":"sec-edgar","filing":"0001104659-18-031869","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1609550/000110465918031869/a4.xml","form_type":"4"}},{"id":3941049,"issuer":{"id":1186,"kind":"organization","name":"Inspire Medical Systems, Inc.","symbol":"INSP"},"owners":[{"id":111954,"kind":"person","name":"Khuong Chau Quang","position":1,"cik":"0001609405","reported_name":"Khuong Chau Quang","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2018-05-10T01:22:26.000Z","date":"2018-05-07","kind":"exercise","acquired":true,"shares":548817,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Shares of Series F Convertible Preferred Stock automatically converted into shares of the Issuer's Common Stock at a 1-for-0.1504 conversion rate immediately prior to the closing of the Issuer's IPO for no additional consideration (subject to the payment of cash in lieu of any fractional shares in accordance with the Issuer's Certificate of Incorporation).  These shares had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These securities are held of record by OrbiMed Private Investments V, LP (\"OPI V\").  OrbiMed Capital GP V LLC (\"GP V\") is the sole general partner of OPI V, and OrbiMed Advisors LLC (\"Advisors\"), a registered adviser under the Investment Advisors Act of 1940, as amended, is the sole managing member of GP V.  By virtue of such relationships, GP V and Advisors may be deemed to have voting and investment power with respect to the securities held by OPI V noted above and as a result may be deemed to beneficially own such securities for purposes of Rule 13d-3 under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\").  Advisors exercised this investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho and Jonathan T. Silverstein, each of whom disclaims beneficial ownership of the Shares held by OPI V. The Reporting Person is an employee of Advisors."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Each of the Reporting Person, GP V and Advisors disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) of the Exchange Act, except to the extent of its or his pecuniary interest therein, if any.  This report shall not be deemed an admission that any such entity or person, including the Reporting Person, is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":2131721,"source":{"system":"sec-edgar","filing":"0001104659-18-031869","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1609550/000110465918031869/a4.xml","form_type":"4"}},{"id":3941048,"issuer":{"id":1186,"kind":"organization","name":"Inspire Medical Systems, Inc.","symbol":"INSP"},"owners":[{"id":111954,"kind":"person","name":"Khuong Chau Quang","position":1,"cik":"0001609405","reported_name":"Khuong Chau Quang","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2018-05-10T01:22:26.000Z","date":"2018-05-07","kind":"exercise","acquired":true,"shares":1582904,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Shares of Series E Convertible Preferred Stock automatically converted into shares of the Issuer's Common Stock at a 1-for-0.1728 conversion rate immediately prior to the closing of the Issuer's initial public offering (\"IPO\") for no additional consideration (subject to the payment of cash in lieu of any fractional shares in accordance with the Issuer's Sixth Amended and Restated Certificate of Incorporation (as amended, the \"Certificate of Incorporation\").  These shares had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These securities are held of record by OrbiMed Private Investments V, LP (\"OPI V\").  OrbiMed Capital GP V LLC (\"GP V\") is the sole general partner of OPI V, and OrbiMed Advisors LLC (\"Advisors\"), a registered adviser under the Investment Advisors Act of 1940, as amended, is the sole managing member of GP V.  By virtue of such relationships, GP V and Advisors may be deemed to have voting and investment power with respect to the securities held by OPI V noted above and as a result may be deemed to beneficially own such securities for purposes of Rule 13d-3 under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\").  Advisors exercised this investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho and Jonathan T. Silverstein, each of whom disclaims beneficial ownership of the Shares held by OPI V. The Reporting Person is an employee of Advisors."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Each of the Reporting Person, GP V and Advisors disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) of the Exchange Act, except to the extent of its or his pecuniary interest therein, if any.  This report shall not be deemed an admission that any such entity or person, including the Reporting Person, is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":1582904,"source":{"system":"sec-edgar","filing":"0001104659-18-031869","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1609550/000110465918031869/a4.xml","form_type":"4"}},{"id":4084649,"issuer":{"id":7801,"kind":"organization","name":"SYNLOGIC, INC."},"owners":[{"id":111954,"kind":"person","name":"Khuong Chau Quang","position":1,"cik":"0001609405","reported_name":"Khuong Chau Quang","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-01-30T21:30:27.000Z","date":"2018-01-26","kind":"grant","acquired":true,"shares":715000,"price":9.75,"value":6971250.0,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"These shares are held of record by OrbiMed Private Investments VI, LP (\"OPI VI\"). OrbiMed Capital GP VI LLC (\"GP VI\") is the sole general partner of OPI VI, and OrbiMed Advisors LLC (\"Advisors\"), a registered adviser under the Investment Advisers Act of 1940, as amended, is the sole managing member of GP VI. By virtue of such relationships, GP VI and Advisors may be deemed to have voting and investment power with respect to the securities held by OPI VI noted above and as a result may be deemed to have beneficial ownership over such securities. Advisors exercises this investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho and Jonathan T. Silverstein, each of whom disclaims beneficial ownership of the shares held by OPI VI. The Reporting Person is an employee of Advisors."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Each of GP VI, Advisors and the Reporting Person disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its or his pecuniary interest therein, if any. This report shall not be deemed an admission that any such entity or person is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":2029996,"source":{"system":"sec-edgar","filing":"0000899243-18-002260","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1527599/000089924318002260/doc4.xml","form_type":"4"}},{"id":4110541,"issuer":{"id":7801,"kind":"organization","name":"SYNLOGIC, INC."},"owners":[{"id":111954,"kind":"person","name":"Khuong Chau Quang","position":1,"cik":"0001609405","reported_name":"Khuong Chau Quang","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2018-01-03T21:36:55.000Z","date":"2017-12-29","kind":"grant","acquired":true,"shares":17143,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options vest and become exercisable in substantially equal installments on each of the first three anniversaries of August 28, 2017 subject to the Reporting Person continuing to provide services to the Issuer through each such vesting date."}],"balance_after":17143,"derivative":{"exercise_price":9.7,"expiration_date":"2027-12-29","underlying":"Common Stock","underlying_shares":17143},"source":{"system":"sec-edgar","filing":"0000899243-18-000280","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1527599/000089924318000280/doc4.xml","form_type":"4"}},{"id":4179273,"issuer":{"id":4452,"kind":"organization","name":"PALVELLA THERAPEUTICS, INC.","symbol":"PVLA"},"owners":[{"id":111954,"kind":"person","name":"Khuong Chau Quang","position":1,"cik":"0001609405","reported_name":"Khuong Chau Quang","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Options (Right to buy)","published_at":"2017-10-27T20:26:13.000Z","date":"2017-10-25","kind":"grant","acquired":true,"shares":6115,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The Reporting Person is an employee of OrbiMed Advisors LLC (\"Advisors\") and is obligated to transfer any shares issued under equity grants made to him by the Issuer, or the economic benefits thereof, to Advisors for the ultimate benefit of OrbiMed Private Investments III, LP and OrbiMed Associates III, LP."}],"balance_after":6115,"derivative":{"exercise_price":4.68,"exercise_date":"2017-10-25","expiration_date":"2027-10-25","underlying":"Common Stock","underlying_shares":6115},"source":{"system":"sec-edgar","filing":"0001562180-17-003339","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1583648/000156218017003339/primarydocument.xml","form_type":"4"}},{"id":4221352,"issuer":{"id":7801,"kind":"organization","name":"SYNLOGIC, INC."},"owners":[{"id":111954,"kind":"person","name":"Khuong Chau Quang","position":1,"cik":"0001609405","reported_name":"Khuong Chau Quang","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2017-08-30T20:08:08.000Z","date":"2017-08-28","kind":"grant","acquired":true,"shares":2857,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests and becomes exercisable in substantially equal installments on each of the first three anniversaries of the Transaction Date, subject to the Reporting Person continuing to provide services to the Issuer through such vesting date."}],"balance_after":2857,"derivative":{"exercise_price":12.07,"expiration_date":"2027-08-28","underlying":"Common Stock","underlying_shares":2857},"source":{"system":"sec-edgar","filing":"0000899243-17-021262","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1527599/000089924317021262/doc4.xml","form_type":"4"}},{"id":4249879,"issuer":{"id":4452,"kind":"organization","name":"PALVELLA THERAPEUTICS, INC.","symbol":"PVLA"},"owners":[{"id":111954,"kind":"person","name":"Khuong Chau Quang","position":1,"cik":"0001609405","reported_name":"Khuong Chau Quang","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2017-07-28T00:27:15.000Z","date":"2017-07-25","kind":"grant","acquired":true,"shares":5018,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The Reporting Person is an employee of OrbiMed Advisors LLC (\"Advisors\") and is obligated to transfer any shares issued under equity grants made to him by the Issuer, or the economic benefits thereof, to Advisors for the ultimate benefit of OrbiMed Private Investments III, LP and OrbiMed Associates III, LP."}],"balance_after":5018,"derivative":{"exercise_price":5.64,"exercise_date":"2017-07-25","expiration_date":"2027-07-25","underlying":"Common Stock","underlying_shares":5018},"source":{"system":"sec-edgar","filing":"0000899243-17-019253","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1583648/000089924317019253/doc4.xml","form_type":"4"}},{"id":4271501,"issuer":{"id":174291,"kind":"organization","name":"Nabriva Therapeutics Legacy plc","symbol":"NBRV"},"owners":[{"id":111954,"kind":"person","name":"Khuong Chau Quang","position":1,"cik":"0001609405","reported_name":"Khuong Chau Quang","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option","published_at":"2017-06-27T21:56:06.000Z","date":"2017-06-23","kind":"other","acquired":true,"shares":10100,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F5","text":"The exercise price is 6.634 Euro."},{"field":"kind","element":"transactionCoding","label":"F2","text":"These shares are held of record by OrbiMed Private Investments V, LP (\"OPI V\"). OrbiMed Advisors LLC (\"Advisors\"), a registered investment adviser under the Investment Advisers Act of 1940, as amended, is the sole managing member of OrbiMed Capital GP V LLC (\"GP V\"), which is the sole general partner of OPI V, which is the majority member of OrbiMed Private Investments V Cooperatief U.A. (\"OPI V Cooperatief\"), which is the sole shareholder of OrbiMed Private Investments V-NB B.V. (\"OPI V- NB\"). OPI V and OPI V-NB hold ADSs and Common Shares, respectively, as described herein. Samuel D. Isaly (\"Isaly\"), a natural person, is the managing member of Advisors and owns a controlling interest in Advisors."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"This option was granted on August 26, 2016. Vesting began on August 31, 2016 and ends on August 31, 2017. One hundred percent (100%) of the option will vest on August 31, 2017."}],"balance_after":10100,"derivative":{"expiration_date":"2026-08-25","underlying":"Ordinary Shares","underlying_shares":10100},"source":{"system":"sec-edgar","filing":"0001104659-17-041905","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1609405/000110465917041905/a4.xml","form_type":"4"}},{"id":4271500,"issuer":{"id":174291,"kind":"organization","name":"Nabriva Therapeutics Legacy plc","symbol":"NBRV"},"owners":[{"id":111954,"kind":"person","name":"Khuong Chau Quang","position":1,"cik":"0001609405","reported_name":"Khuong Chau Quang","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Ordinary Shares","published_at":"2017-06-27T21:56:06.000Z","date":"2017-06-23","kind":"other","acquired":true,"shares":2241660,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Reflects the beneficial ownership of the reporting person following the succession pursuant to Rule 12g-3(a) of the Securities Exchange Act of 1934, as amended, of Nabriva Therapeutics plc to Nabriva Therapeutics AG.  The succession occurred following the conclusion, on June 23, 2017, of a tender offer related to the exchange of American depositary shares and common shares of Nabriva Therapeutics AG for ordinary shares of Nabriva Therapeutics plc."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The Reporting Person, an employee of Advisors, has been designated by Advisors to serve on the issuer's board of directors and disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\") except to the extent of his pecuniary interest therein, if any. This report on Form 3 shall not be deemed any admission that any such entity or person, including the Reporting Person, is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act or for any other purpose."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"These shares are held of record by OPI V-NB."}],"balance_after":2241660,"source":{"system":"sec-edgar","filing":"0001104659-17-041905","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1609405/000110465917041905/a4.xml","form_type":"4"}},{"id":4271499,"issuer":{"id":174291,"kind":"organization","name":"Nabriva Therapeutics Legacy plc","symbol":"NBRV"},"owners":[{"id":111954,"kind":"person","name":"Khuong Chau Quang","position":1,"cik":"0001609405","reported_name":"Khuong Chau Quang","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Ordinary Shares","published_at":"2017-06-27T21:56:06.000Z","date":"2017-06-23","kind":"other","acquired":true,"shares":1677940,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Reflects the beneficial ownership of the reporting person following the succession pursuant to Rule 12g-3(a) of the Securities Exchange Act of 1934, as amended, of Nabriva Therapeutics plc to Nabriva Therapeutics AG.  The succession occurred following the conclusion, on June 23, 2017, of a tender offer related to the exchange of American depositary shares and common shares of Nabriva Therapeutics AG for ordinary shares of Nabriva Therapeutics plc."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are held of record by OrbiMed Private Investments V, LP (\"OPI V\"). OrbiMed Advisors LLC (\"Advisors\"), a registered investment adviser under the Investment Advisers Act of 1940, as amended, is the sole managing member of OrbiMed Capital GP V LLC (\"GP V\"), which is the sole general partner of OPI V, which is the majority member of OrbiMed Private Investments V Cooperatief U.A. (\"OPI V Cooperatief\"), which is the sole shareholder of OrbiMed Private Investments V-NB B.V. (\"OPI V- NB\"). OPI V and OPI V-NB hold ADSs and Common Shares, respectively, as described herein. Samuel D. Isaly (\"Isaly\"), a natural person, is the managing member of Advisors and owns a controlling interest in Advisors."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The Reporting Person, an employee of Advisors, has been designated by Advisors to serve on the issuer's board of directors and disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\") except to the extent of his pecuniary interest therein, if any. This report on Form 3 shall not be deemed any admission that any such entity or person, including the Reporting Person, is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act or for any other purpose."}],"balance_after":1677940,"source":{"system":"sec-edgar","filing":"0001104659-17-041905","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1609405/000110465917041905/a4.xml","form_type":"4"}},{"id":4343235,"issuer":{"id":4452,"kind":"organization","name":"PALVELLA THERAPEUTICS, INC.","symbol":"PVLA"},"owners":[{"id":111954,"kind":"person","name":"Khuong Chau Quang","position":1,"cik":"0001609405","reported_name":"Khuong Chau Quang","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2017-04-27T22:09:56.000Z","date":"2017-04-25","kind":"grant","acquired":true,"shares":10546,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The Reporting Person is an employee of OrbiMed Advisors LLC (\"Advisors\") and is obligated to transfer any shares issued under equity grants made to him by the Issuer, or the economic benefits thereof, to Advisors for the ultimate benefit of OrbiMed Private Investments III, LP and OrbiMed Associates III, LP."}],"balance_after":10546,"derivative":{"exercise_price":2.32,"exercise_date":"2017-04-25","expiration_date":"2027-04-25","underlying":"Common Stock","underlying_shares":10546},"source":{"system":"sec-edgar","filing":"0000899243-17-011043","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1583648/000089924317011043/doc4.xml","form_type":"4"}}],"next_cursor":"2017-04-27T22:09:56.000000Z,4343235"}